<!DOCTYPE html>
<html>
<head>

      <meta http-equiv="Content-Type" content="text/html; charset=utf-8">

        <script> var url = encodeURIComponent('https://www.webmd.com/dna/the-turning-point/cad-pad');</script>

        <script> var body_html = '<body> <header ></header> <div ><div ><div > <div > <div > <h1 ><a >THE TURNING POINT</a></h1> <div > <ul> <li> <a > AFIB </a> </li> <li> <a > DVT/PE </a> </li> <li> <a > CAD </a> </li> </ul> </div> </div> <div > <div > <div > <h3 >You can help lower your risk of CAD-related events</h3> </div> </div> <div > What is CAD? <p>Coronary artery disease, or CAD, is a heart condition that may be more common than you think.</p> <div > <div > <p>More than 370,000 PEOPLE DIE FROM CAD, the most common heart disease in the US, each year.</p> </div> <div > <p>Up to 8.5 MILLION PEOPLE ARE AFFECTED BY PAD, and about 75% are not even aware of it.</p> </div> </div> <p >Simply put, CAD is the hardening of arteries, usually caused by the buildup of plaque, around the heart, and there are a number of risk factors that contribute to it. “High blood pressure, high cholesterol, diabetes, smoking, and obesity are the major modifiable risk factors, and the risk factors you can't control include age and family history," says Dr. Sanjum Sethi, a cardiologist at Columbia University Medical Center.</p> <p>Peripheral artery disease (PAD) occurs when arteries away from the heart, including those that deliver blood to the arms and legs, harden in a similar fashion to CAD, and there is a strong correlation between the two.</p> <div > <p >“When somebody is at risk for depositing plaques, they deposit plaques in more than one area of the body. So often, if you have CAD, you are at increased risk for having PAD."</p> <p >Dr. Sanjum Sethi</p> </div> <div > Learn About CAD and PAD <p>In people with CAD or PAD, cholesterol, white blood cells, and other substances build up inside damaged artery walls, forming plaque. It's similar to the sludge inside of pipes. As you can imagine, this makes it difficult for blood to travel through these arteries, reducing essential blood flow to the heart. In CAD, this can cause symptoms like chest pain, shortness of breath, and even blood clots. “When I talk to patients, I'm very interested in how much functional activity they are able to do, such as walking around and other daily activities, without getting tired or winded. This is important in terms of understanding whether they have [the] disease and how significant it is," says Dr. Sethi.</p> </div> <div > <div><h2>CAD and PAD risk factors include</h2></div> <div > <div > <h3>SMOKING</h3> </div> <div > <h3>DIABETES</h3> </div> <div > <h3>HIGH CHOLESTEROL</h3> </div> </div> <div > <div > <h3>HIGH BLOOD PRESSURE</h3> </div> <div > <h3>FAMILY HISTORY OF HEART DISEASE</h3> </div> <div > <h3>BEING OVERWEIGHT</h3> </div> </div> </div> </div> <div > <div> Symptoms <p>Blood clots are a cause for concern for people with CAD or PAD because there is a risk that plaques will rupture inside the artery. Once this happens, your body's blood clotting response is triggered, and a clot forms around the ruptured plaque. For people with CAD, this blood clot can block blood flow to your heart, causing a heart attack, or break off and travel to your brain, causing a stroke. With PAD, a blood clot can form in an artery of the limbs, such as the leg, causing pain or a more serious event that requires amputation. These are serious consequences—some of which can lead to death—all of which can be avoided.</p> </div> <div > <p >If you've been diagnosed with CAD or PAD or a had a stent procedure or bypass surgery, keep an eye out for symptoms:</p> <div > <div > <h4>CAD</h4> <ul> <li>Chest pain</li> <li>Shortness of breath</li> <li>Heart fluttering, pounding or racing</li> <li>Fatigue</li> <li>Nausea or vomiting</li> </ul> </div> </div> <div > <div > <h4>PAD</h4> <ul> <li>Leg cramping, numbness, weakness, or coldness</li> <li>Sores on toes, or legs</li> <li>Change in hair/nail growth on legs or feet</li> <li>Change in color or shine on skin of legs</li> <li>No pulse or weak pulse in legs or feet</li> <li>Erectile dysfunction in men</li> </ul> </div> </div> <div > <p >These risk factors cause damage and inflammation to the artery wall, increasing the chance of a blood clot</p> </div> <p >Even if you don't experience symptoms, you can still be at risk—especially if you've been diagnosed with CAD, had a heart attack, or received a stent or bypass procedure. </p> </div> <div > <p >“I use all of the risk factors to understand what a patient's risk is, and based on that, we come up with a treatment plan—whether it be medical, surgical, or invasive—that is tailored to them."</p> <p >Dr. Sanjum Sethi</p> </div> <div > Understanding Treatments and Procedures <p>There are several procedures that can help restore blood flow in a blocked artery. These include angioplasty, stent implantation, and coronary artery bypass graft surgery (CABG). Angioplasty opens a blocked artery by inflating a tiny balloon inside the blockage. Stent implantation permanently props open a blocked artery with a tiny wire mesh tube that is placed during an angioplasty. CABG reroutes blood around a completely blocked artery using a blood vessel from another part of your body. These procedures may be life-saving, but they do not fix you for good, and you are still at risk even if a heart attack or stent procedure happened a while ago.</p> <p>Once you have an event like a heart attack or stent procedure, your doctor will likely put you on a treatment plan that includes several medications. These medications may include anticoagulants, or blood thinners, which help prevent blood clots from forming. Another medication is antiplatelets that, like aspirin, keep platelets from sticking together. Many people take aspirin as a blood thinner, but it may not be enough. A large study of almost 40,000 people showed that even though more than half were taking aspirin, the number of heart attacks, strokes, and cardiovascular deaths more than doubled over a two-year period.*</p> <p >*According to data from the REACH Registry.</p> </div> <div > Help Reduce Your Risk of Cardiovascular Events <p>XARELTO<sup>®</sup> 2.5 mg twice daily, when taken with low-dose aspirin,<sup>†</sup> is proven to help further reduce the risk of blood clots that can cause heart attack, stroke, or cardiovascular death in people with chronic CAD or PAD. In a clinical trial, almost 96% of people with chronic CAD or PAD taking XARELTO<sup>®</sup> did not have a cardiovascular event.<sup>‡</sup></p> <p ><sup>†</sup>Low-dose aspirin = 75-mg-100-mg aspirin tablet.</p> <p ><sup>‡</sup>Rate of first event (heart attack, stroke, cardiovascular death) was 4.1% for people taking XARELTO<sup>®</sup> plus aspirin vs. 5.4% for aspirin alone. Patients were followed for an average of 23 months. </p> </div> </div> <div > <div > <div > <div > <div > <h2>What do I need to know about CAD?</h2> <p>CAD (coronary artery disease) is a condition resulting from atherosclerosis, or a hardening of the arteries, which is caused by the buildup of plaque in the arteries that supply blood to the heart—like sludge on the inside of pipes. These plaques can rupture, causing a blood clot to form.</p> <p>If you've been diagnosed with CAD, had a heart attack, or had a stent or bypass procedure, you may still have an underlying risk for blood clots that can cause a cardiovascular event. </p> </div> </div> <div > <div > <h2>What are the consequences of CAD?</h2> <p>The risk for blood clots in people with CAD is high, and these blood clots can break free and travel through the arteries, which can lead to serious cardiovascular events like stroke and heart attack.</p> <p>Even if you had a stent procedure, bypass surgery, or a heart attack a while ago, you're taking medication, and you're trying to eat right and stay active, the risk for a cardiovascular event still increases over time.</p> </div> </div> <div > <div > <h2>What is PAD, and how is it related to CAD?</h2> <p>For people with CAD, a blood clot occurs in the arteries that supply blood to the heart, and for people with peripheral artery disease (PAD), a blood clot occurs in the arteries of the limbs—usually the legs.</p> <p>Both CAD and PAD are the result of hardening of the arteries caused by damage or inflammation of the artery wall due to certain health conditions or risk factors, including diabetes, high blood pressure, high cholesterol, smoking, or a family history of heart disease.</p> </div> </div> <div > <div > <h2>Can I have both CAD and PAD?</h2> <p>It is common for people with CAD to also have PAD. In addition to CAD and PAD sharing similar risk factors, people who have both CAD and PAD have an even higher risk for cardiovascular events than people with CAD or PAD alone, so it's important to ask your doctor about an ankle-brachial index screening test for PAD.</p> </div> </div> <div > <div > <h2>What can I do to lower my risk of developing CAD or PAD?</h2> <p>There are simple things you can do like exercising, maintaining a healthy weight, eating healthy, and managing stress levels. If you are a smoker, quit smoking. And if you have other conditions like diabetes or high cholesterol, manage those as well.</p> </div> </div> <div > <div > <h2>What are the treatments for CAD and PAD?</h2> <p>Some people get a stent placed in their artery or have bypass surgery, while others take blood thinners in addition to a stent.</p> <p>Some blood thinners, like aspirin, keep platelets from sticking together, while others slow down the blood's clotting process—all to reduce the chance of blood clots that can cause heart attack or stroke.</p> </div> </div> <div > <div > <h2>What treatment is best for me? And is aspirin alone enough?</h2> <p>XARELTO<sup>®</sup>, when taken with low-dose aspirin,<sup>*</sup> is proven to help further reduce the risk of blood clots that can cause heart attack, stroke, or cardiovascular death in people with chronic CAD.</p> <p>While aspirin can help, a recent study showed it may not be enough to manage the underlying risk of blood clots returning. In a clinical trial, almost 96% of people taking XARELTO<sup>®</sup> 2.5 mg twice daily in combination with low-dose aspirin did not have a cardiovascular event.<sup>†</sup></p> <p ><sup>*</sup>Low-dose aspirin = 75-mg to 100-mg aspirin tablet.</p> <p ><sup>†</sup>Rate of first event (heart attack, stroke, cardiovascular death) was 4.1% for people taking XARELTO<sup>®</sup> plus aspirin vs. 5.4% for aspirin alone. Patients were followed for an average of 23 months.</p> </div> </div> <div > <div > <h2>What else can I do to help lower my risk of cardiovascular events?</h2> <p> CAD and PAD have serious consequences, and both conditions get worse over time. Ask for support from your loved ones to encourage healthy habits.</p> <p>Most importantly, stay in touch with your healthcare team and take your medications as prescribed by your doctor.</p> </div> </div> </div> </div> <p>If you are one of the millions who have CAD, you know how important it is to take preventative measures to remain as healthy as possible. Remember, even if you are eating healthy, staying active, and your event occurred a long time ago, you are still at risk. Talk to your doctor to better understand your risk for blood clots that can lead to a cardiovascular event and learn which treatments are best for you.</p> <div > <div > <p>WHILE ASPIRIN CAN HELP, IT MAY NOT BE ENOUGH. In a large study that included people with CAD or PAD, there was a more than 2X INCREASE IN HEART ATTACKS, STROKE, AND CARDIOVASCULAR DEATH with or without aspirin.* Talk to your doctor about other treatment options to lower your risk for stroke.</p> <p >*According to data from the REACH Registry.</p> <p><span>In a clinical trial, almost 96% of people<sup>†</sup> with chronic CAD or PAD taking XARELTO<sup>®</sup> 2.5 mg twice daily in combination with low-dose aspirin<sup>§</sup> once daily did not have a heart attack, stroke, or die from a cardiovascular event.</span></p> <p ><sup>†</sup>The rate of the first event was 4.1% for people taking XARELTO<sup>®</sup> plus aspirin vs 5.4% for aspirin alone. Patients were followed for an average of 23 months. <sup>§</sup>Low-dose aspirin = 75-mg-100-mg aspirin tablet.</p> </div> </div> <div > <div ><p>YOUR DOCTOR IS ALWAYS YOUR BEST RESOURCE. He or she knows your situation best and can help you determine a treatment plan.</p></div> </div> </div> <div > <div > <h1>Find out more about how to help reduce your risk of cardiovascular events with XARELTO<sup>®</sup></h1> Learn More </div> </div> </div> </div> </div> </div><div ><div > <div > <div > <div > <div > <div > <div > WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used to:</p> <ul> <li> reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body </li> <li> treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE) </li> <li> reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months </li> </ul> <p>XARELTO<sup>®</sup> is used with low dose aspirin to:</p> <ul> <li> reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> <div > <div >WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used to:</p> <ul> <li>reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body</li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> <div > <div >WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used to:</p> <ul> <li>treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE)</li> <li>reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months</li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> <div > <div >WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used with low dose aspirin to:</p> <ul> <li>reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> </div> <div > <h3 >IMPORTANT SAFETY INFORMATION</h3> <p >WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT XARELTO<sup>®</sup>?</p> <p> XARELTO<sup>®</sup> may cause serious side effects, including: </p> <ul > <li> Increased risk of blood clots if you stop taking XARELTO<sup>®</sup>. People with atrial fibrillation (an irregular heart beat) that is not caused by a heart valve problem (nonvalvular) are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a stroke, or to other parts of the body. XARELTO<sup>®</sup> lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking XARELTO<sup>®</sup>, you may have increased risk of forming a clot in your blood. </li> <li > Do not stop taking XARELTO<sup>®</sup> without talking to the doctor who prescribes it for you. Stopping XARELTO<sup>®</sup> increases your risk of having a stroke. If you have to stop taking XARELTO<sup>®</sup>, your doctor may prescribe another blood thinner medicine to prevent a blood clot from forming. </li> <li> Increased risk of bleeding. XARELTO<sup>®</sup> can cause bleeding which can be serious, and may lead to death. This is because XARELTO<sup>®</sup> is a blood thinner medicine (anticoagulant) that lowers blood clotting. During treatment with XARELTO<sup>®</sup> you are likely to bruise more easily, and it may take longer for bleeding to stop. You may be at higher risk of bleeding if you take XARELTO<sup>®</sup> and have certain other medical problems. </li> </ul> <p > You may have a higher risk of bleeding if you take XARELTO<sup>®</sup> and take other medicines that increase your risk of bleeding, including: </p> <ul > <li>Aspirin or aspirin-containing products</li> <li>Long-term (chronic) use of non-steroidal anti-inflammatory drugs (NSAIDs)</li> <li>Warfarin sodium (Coumadin<sup>®</sup>, Jantoven<sup>®</sup>)</li> <li>Any medicine that contains heparin</li> <li>Clopidogrel (Plavix<sup>®</sup>)</li> <li>Selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)</li> <li>Other medicines to prevent or treat blood clots</li> </ul> <p > Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above. </p> <p > Call your doctor or get medical help right away if you develop any of these signs or symptoms of bleeding: </p> <ul > <li>Unexpected bleeding or bleeding that lasts a long time, such as:</li> </ul> <ul > <li>Nosebleeds that happen often</li> <li>Unusual bleeding from gums</li> <li>Menstrual bleeding that is heavier than normal, or vaginal bleeding</li> </ul> <ul > <li>Bleeding that is severe or you cannot control</li> <li>Red, pink, or brown urine</li> <li>Bright red or black stools (looks like tar)</li> <li>Cough up blood or blood clots</li> <li>Vomit blood or your vomit looks like "coffee grounds"</li> <li>Headaches, feeling dizzy or weak</li> <li >Pain, swelling, or new drainage at wound sites</li> </ul> <li > Spinal or epidural blood clots (hematoma). People who take a blood thinner medicine (anticoagulant) like XARELTO<sup>®</sup>, and have medicine injected into their spinal and epidural area, or have a spinal puncture, have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis). Your risk of developing a spinal or epidural blood clot is higher if: <ul > <li> A thin tube called an epidural catheter is placed in your back to give you certain medicine </li> <li> You take NSAIDs or a medicine to prevent blood from clotting </li> <li> You have a history of difficult or repeated epidural or spinal punctures </li> <li> You have a history of problems with your spine or have had surgery on your spine </li> </ul> </li> <p > If you take XARELTO<sup>®</sup> and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots. Tell your doctor right away if you have back pain, tingling, numbness, muscle weakness (especially in your legs and feet), or loss of control of the bowels or bladder (incontinence). </p> <p> XARELTO<sup>®</sup> is not for use in people with artificial heart valves. </p> <p> XARELTO<sup>®</sup> is not for use in people with antiphospholipid syndrome (APS), especially with positive triple antibody testing. </p> <p > ​​Do not take XARELTO<sup>®</sup> if you: </p> <ul > <li> Currently have certain types of abnormal bleeding. Talk to your doctor before taking XARELTO<sup>®</sup> if you currently have unusual bleeding. </li> <li> Are allergic to rivaroxaban or any of the ingredients of XARELTO<sup>®</sup>. </li> </ul> <p > ​​Before taking XARELTO<sup>®</sup>, tell your doctor about all your medical conditions, including if you: </p> <ul > <li> Have ever had bleeding problems </li> <li> Have liver or kidney problems </li> <li> Have antiphospholipid syndrome (APS) </li> <li> Are pregnant or plan to become pregnant. It is not known if XARELTO<sup>®</sup> will harm your unborn baby. <ul> <li> Tell your doctor right away if you become pregnant during treatment with XARELTO<sup>®</sup>. Taking XARELTO<sup>®</sup> while you are pregnant may increase the risk of bleeding in you or in your unborn baby. </li> <li> If you take XARELTO<sup>®</sup> during pregnancy, tell your doctor right away if you have any signs or symptoms of bleeding or blood loss. See “What is the most important information I should know about XARELTO<sup>®</sup>?” for signs and symptoms of bleeding. </li> </ul> </li> <li> Are breastfeeding or plan to breastfeed. XARELTO<sup>®</sup> may pass into your breast milk. Talk to your doctor about the best way to feed your baby during treatment with XARELTO<sup>®</sup>. </li> </ul> <p> Tell all of your doctors and dentists that you are taking XARELTO<sup>®</sup>. They should talk to the doctor who prescribed XARELTO<sup>®</sup> for you before you have any surgery, medical or dental procedure. </p> <p> Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements<b>. </b> </p> <p> Some of your other medicines may affect the way XARELTO<sup>®</sup> works, causing side effects. Certain medicines may increase your risk of bleeding. See “What is the most important information I should know about XARELTO<sup>®</sup>?” </p> <p> HOW SHOULD I TAKE XARELTO<sup>®</sup>? </p> <ul > <li> Take XARELTO<sup>®</sup> exactly as prescribed by your doctor. </li> <li> Do not change your dose or stop taking XARELTO<sup>®</sup> unless your doctor tells you to. Your doctor may change your dose if needed. </li> <li> Your doctor will decide how long you should take XARELTO<sup>®</sup>. </li> <li> XARELTO<sup>®</sup> may need to be stopped for one or more days before any surgery or medical or dental procedure. Your doctor will tell you when to stop taking XARELTO<sup>®</sup> and when to start taking XARELTO<sup>®</sup> again after your surgery or procedure. </li> <li> If you need to stop taking XARELTO<sup>®</sup> for any reason, talk to the doctor who prescribed XARELTO<sup>®</sup> to you to find out when you should stop taking it. Do not stop taking XARELTO<sup>®</sup> without first talking to the doctor who prescribes it to you. </li> <li> If you have difficulty swallowing XARELTO<sup>®</sup> tablets whole, talk to your doctor about other ways to take XARELTO<sup>®</sup>. </li> <li> Do not run out of XARELTO<sup>®</sup>. Refill your prescription of XARELTO<sup>®</sup> before you run out. When leaving the hospital following a hip or knee replacement, be sure that you will have XARELTO<sup>®</sup> available to avoid missing any doses. </li> <li> If you take too much XARELTO<sup>®</sup>, go to the nearest hospital emergency room or call your doctor right away. </li> </ul> <p > If you take XARELTO<sup>®</sup> for:​ </p> <ul > <ul > <li > Atrial Fibrillation that is not caused by a heart valve problem: <ul > <li > Take XARELTO<sup>®</sup> 1 time a day with your evening meal. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li > Blood clots in the veins of your legs or lungs: <ul > <li > Take XARELTO<sup>® </sup>1 or 2 times a day as prescribed by your doctor. </li> <li > For the 10-mg dose, XARELTO<sup>®</sup> may be taken with or without food. </li> <li > For the 15-mg and 20-mg doses, take XARELTO<sup>®</sup> with food at the same time each day. </li> <li > If you miss a dose: <ul > <li> If you take the 15-mg dose of XARELTO<sup>®</sup> 2 times a day (a total of 30 mg of XARELTO<sup>®</sup> in 1 day): Take XARELTO<sup>®</sup> as soon as you remember on the same day. You may take 2 doses at the same time to make up for the missed dose. Take your next dose at your regularly scheduled time. </li> <li> If you take XARELTO<sup>®</sup> 1 time a day: Take XARELTO<sup>®</sup> as soon as you remember on the same day. Take your next dose at your regularly scheduled time.​ </li> </ul> </li> </ul> </li> <li > Hip or knee replacement surgery: <ul > <li > Take XARELTO<sup>®</sup> 1 time a day with or without food. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li > Blood clots in people hospitalized for an acute illness: <ul> <li > Take XARELTO<sup>®</sup> 1 time a day, with or without food, while you are in the hospital and after you are discharged as prescribed by your doctor. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li > Reducing the risk of serious heart problems, heart attack and stroke in coronary artery disease or peripheral artery disease: <ul> <li > Take XARELTO<sup>®</sup> 2.5 mg 2 times a day with or without food. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take your next dose at your regularly scheduled time. </li> <li > Take aspirin 75 to 100 mg once daily as instructed by your doctor. </li> </ul> </li> </ul> </ul> <div > <p> WHAT ARE THE POSSIBLE SIDE EFFECTS OF <span >XARELTO<sup>®</sup>?</span> </p> <p > XARELTO<sup>®</sup> may cause serious side effects: </p> <ul> <li> See “What is the most important information I should know about XARELTO<sup>®</sup>?” </li> </ul> <p> The most common side effect of XARELTO<sup>®</sup> was bleeding. </p> <p> Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Janssen Pharmaceuticals, Inc., at 1-800-JANSSEN (1-800-526-7736). </p> <p> Please read full Prescribing Information, including Boxed Warnings, and Medication Guide for XARELTO<sup>®</sup>. </p> <p> Trademarks are those of their respective owners. </p> <p > cp-53637v6 </p> </div> </div> </div> </div> </div></div><div > <div > <p>© Janssen Pharmaceuticals, Inc. 2021May 2021cp-113688v4</p> </div> </div></div></div> <main > </main> <div ><div ><div >WebMD does not endorse any specific product, service, or treatment.</div></div><div ><div > <div > Show More </div> <div > <div ><div > <div > <div > <div > <div > <div > WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used to:</p> <ul> <li> reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body </li> <li> treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE) </li> <li> reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months </li> </ul> <p>XARELTO<sup>®</sup> is used with low dose aspirin to:</p> <ul> <li> reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> <div > <div >WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used to:</p> <ul> <li>reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body</li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> <div > <div >WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used to:</p> <ul> <li>treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE)</li> <li>reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months</li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> <div > <div >WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used with low dose aspirin to:</p> <ul> <li>reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> </div> <div > <h3 >IMPORTANT SAFETY INFORMATION</h3> <p >WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT XARELTO<sup>®</sup>?</p> <p> XARELTO<sup>®</sup> may cause serious side effects, including: </p> <ul > <li> Increased risk of blood clots if you stop taking XARELTO<sup>®</sup>. People with atrial fibrillation (an irregular heart beat) that is not caused by a heart valve problem (nonvalvular) are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a stroke, or to other parts of the body. XARELTO<sup>®</sup> lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking XARELTO<sup>®</sup>, you may have increased risk of forming a clot in your blood. </li> <li > Do not stop taking XARELTO<sup>®</sup> without talking to the doctor who prescribes it for you. Stopping XARELTO<sup>®</sup> increases your risk of having a stroke. If you have to stop taking XARELTO<sup>®</sup>, your doctor may prescribe another blood thinner medicine to prevent a blood clot from forming. </li> <li> Increased risk of bleeding. XARELTO<sup>®</sup> can cause bleeding which can be serious, and may lead to death. This is because XARELTO<sup>®</sup> is a blood thinner medicine (anticoagulant) that lowers blood clotting. During treatment with XARELTO<sup>®</sup> you are likely to bruise more easily, and it may take longer for bleeding to stop. You may be at higher risk of bleeding if you take XARELTO<sup>®</sup> and have certain other medical problems. </li> </ul> <p > You may have a higher risk of bleeding if you take XARELTO<sup>®</sup> and take other medicines that increase your risk of bleeding, including: </p> <ul > <li>Aspirin or aspirin-containing products</li> <li>Long-term (chronic) use of non-steroidal anti-inflammatory drugs (NSAIDs)</li> <li>Warfarin sodium (Coumadin<sup>®</sup>, Jantoven<sup>®</sup>)</li> <li>Any medicine that contains heparin</li> <li>Clopidogrel (Plavix<sup>®</sup>)</li> <li>Selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)</li> <li>Other medicines to prevent or treat blood clots</li> </ul> <p > Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above. </p> <p > Call your doctor or get medical help right away if you develop any of these signs or symptoms of bleeding: </p> <ul > <li>Unexpected bleeding or bleeding that lasts a long time, such as:</li> </ul> <ul > <li>Nosebleeds that happen often</li> <li>Unusual bleeding from gums</li> <li>Menstrual bleeding that is heavier than normal, or vaginal bleeding</li> </ul> <ul > <li>Bleeding that is severe or you cannot control</li> <li>Red, pink, or brown urine</li> <li>Bright red or black stools (looks like tar)</li> <li>Cough up blood or blood clots</li> <li>Vomit blood or your vomit looks like "coffee grounds"</li> <li>Headaches, feeling dizzy or weak</li> <li >Pain, swelling, or new drainage at wound sites</li> </ul> <li > Spinal or epidural blood clots (hematoma). People who take a blood thinner medicine (anticoagulant) like XARELTO<sup>®</sup>, and have medicine injected into their spinal and epidural area, or have a spinal puncture, have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis). Your risk of developing a spinal or epidural blood clot is higher if: <ul > <li> A thin tube called an epidural catheter is placed in your back to give you certain medicine </li> <li> You take NSAIDs or a medicine to prevent blood from clotting </li> <li> You have a history of difficult or repeated epidural or spinal punctures </li> <li> You have a history of problems with your spine or have had surgery on your spine </li> </ul> </li> <p > If you take XARELTO<sup>®</sup> and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots. Tell your doctor right away if you have back pain, tingling, numbness, muscle weakness (especially in your legs and feet), or loss of control of the bowels or bladder (incontinence). </p> <p> XARELTO<sup>®</sup> is not for use in people with artificial heart valves. </p> <p> XARELTO<sup>®</sup> is not for use in people with antiphospholipid syndrome (APS), especially with positive triple antibody testing. </p> <p > ​​Do not take XARELTO<sup>®</sup> if you: </p> <ul > <li> Currently have certain types of abnormal bleeding. Talk to your doctor before taking XARELTO<sup>®</sup> if you currently have unusual bleeding. </li> <li> Are allergic to rivaroxaban or any of the ingredients of XARELTO<sup>®</sup>. </li> </ul> <p > ​​Before taking XARELTO<sup>®</sup>, tell your doctor about all your medical conditions, including if you: </p> <ul > <li> Have ever had bleeding problems </li> <li> Have liver or kidney problems </li> <li> Have antiphospholipid syndrome (APS) </li> <li> Are pregnant or plan to become pregnant. It is not known if XARELTO<sup>®</sup> will harm your unborn baby. <ul> <li> Tell your doctor right away if you become pregnant during treatment with XARELTO<sup>®</sup>. Taking XARELTO<sup>®</sup> while you are pregnant may increase the risk of bleeding in you or in your unborn baby. </li> <li> If you take XARELTO<sup>®</sup> during pregnancy, tell your doctor right away if you have any signs or symptoms of bleeding or blood loss. See “What is the most important information I should know about XARELTO<sup>®</sup>?” for signs and symptoms of bleeding. </li> </ul> </li> <li> Are breastfeeding or plan to breastfeed. XARELTO<sup>®</sup> may pass into your breast milk. Talk to your doctor about the best way to feed your baby during treatment with XARELTO<sup>®</sup>. </li> </ul> <p> Tell all of your doctors and dentists that you are taking XARELTO<sup>®</sup>. They should talk to the doctor who prescribed XARELTO<sup>®</sup> for you before you have any surgery, medical or dental procedure. </p> <p> Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements<b>. </b> </p> <p> Some of your other medicines may affect the way XARELTO<sup>®</sup> works, causing side effects. Certain medicines may increase your risk of bleeding. See “What is the most important information I should know about XARELTO<sup>®</sup>?” </p> <p> HOW SHOULD I TAKE XARELTO<sup>®</sup>? </p> <ul > <li> Take XARELTO<sup>®</sup> exactly as prescribed by your doctor. </li> <li> Do not change your dose or stop taking XARELTO<sup>®</sup> unless your doctor tells you to. Your doctor may change your dose if needed. </li> <li> Your doctor will decide how long you should take XARELTO<sup>®</sup>. </li> <li> XARELTO<sup>®</sup> may need to be stopped for one or more days before any surgery or medical or dental procedure. Your doctor will tell you when to stop taking XARELTO<sup>®</sup> and when to start taking XARELTO<sup>®</sup> again after your surgery or procedure. </li> <li> If you need to stop taking XARELTO<sup>®</sup> for any reason, talk to the doctor who prescribed XARELTO<sup>®</sup> to you to find out when you should stop taking it. Do not stop taking XARELTO<sup>®</sup> without first talking to the doctor who prescribes it to you. </li> <li> If you have difficulty swallowing XARELTO<sup>®</sup> tablets whole, talk to your doctor about other ways to take XARELTO<sup>®</sup>. </li> <li> Do not run out of XARELTO<sup>®</sup>. Refill your prescription of XARELTO<sup>®</sup> before you run out. When leaving the hospital following a hip or knee replacement, be sure that you will have XARELTO<sup>®</sup> available to avoid missing any doses. </li> <li> If you take too much XARELTO<sup>®</sup>, go to the nearest hospital emergency room or call your doctor right away. </li> </ul> <p > If you take XARELTO<sup>®</sup> for:​ </p> <ul > <ul > <li > Atrial Fibrillation that is not caused by a heart valve problem: <ul > <li > Take XARELTO<sup>®</sup> 1 time a day with your evening meal. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li > Blood clots in the veins of your legs or lungs: <ul > <li > Take XARELTO<sup>® </sup>1 or 2 times a day as prescribed by your doctor. </li> <li > For the 10-mg dose, XARELTO<sup>®</sup> may be taken with or without food. </li> <li > For the 15-mg and 20-mg doses, take XARELTO<sup>®</sup> with food at the same time each day. </li> <li > If you miss a dose: <ul > <li> If you take the 15-mg dose of XARELTO<sup>®</sup> 2 times a day (a total of 30 mg of XARELTO<sup>®</sup> in 1 day): Take XARELTO<sup>®</sup> as soon as you remember on the same day. You may take 2 doses at the same time to make up for the missed dose. Take your next dose at your regularly scheduled time. </li> <li> If you take XARELTO<sup>®</sup> 1 time a day: Take XARELTO<sup>®</sup> as soon as you remember on the same day. Take your next dose at your regularly scheduled time.​ </li> </ul> </li> </ul> </li> <li > Hip or knee replacement surgery: <ul > <li > Take XARELTO<sup>®</sup> 1 time a day with or without food. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li > Blood clots in people hospitalized for an acute illness: <ul> <li > Take XARELTO<sup>®</sup> 1 time a day, with or without food, while you are in the hospital and after you are discharged as prescribed by your doctor. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li > Reducing the risk of serious heart problems, heart attack and stroke in coronary artery disease or peripheral artery disease: <ul> <li > Take XARELTO<sup>®</sup> 2.5 mg 2 times a day with or without food. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take your next dose at your regularly scheduled time. </li> <li > Take aspirin 75 to 100 mg once daily as instructed by your doctor. </li> </ul> </li> </ul> </ul> <div > <p> WHAT ARE THE POSSIBLE SIDE EFFECTS OF <span >XARELTO<sup>®</sup>?</span> </p> <p > XARELTO<sup>®</sup> may cause serious side effects: </p> <ul> <li> See “What is the most important information I should know about XARELTO<sup>®</sup>?” </li> </ul> <p> The most common side effect of XARELTO<sup>®</sup> was bleeding. </p> <p> Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Janssen Pharmaceuticals, Inc., at 1-800-JANSSEN (1-800-526-7736). </p> <p> Please read full <a >Prescribing Information</a>, including Boxed Warnings, and <a >Medication Guide</a> for XARELTO<sup>®</sup>. </p> <p> Trademarks are those of their respective owners. </p> <p > cp-53637v6 </p> </div> </div> </div> </div> </div></div> </div> </div> </div></div> </body>'</script>

      </head>
        <body class="valid" valid="valid" title="valid: True, node: 1, level: 1" node_number="1"> <header class="valid" valid="valid" title="valid: True, node: 2, level: 2" node_number="2"/> <div class="valid" valid="valid" title="valid: True, node: 3, level: 2" node_number="3"><div class="valid" valid="valid" title="valid: True, node: 4, level: 3" node_number="4"><div class="valid" valid="valid" title="valid: True, node: 5, level: 4" node_number="5"> <div class="valid" valid="valid" title="valid: True, node: 6, level: 5" node_number="6"> <div class="valid" valid="valid" title="valid: True, node: 7, level: 6" node_number="7"> <h1 class="valid" valid="valid" title="valid: True, node: 8, level: 7" node_number="8"><a class="valid" valid="valid" title="valid: True, node: 9, level: 8" node_number="9">THE TURNING POINT</a></h1> <div class="valid" valid="valid" title="valid: True, node: 10, level: 7" node_number="10"> <ul class="valid" valid="valid" title="valid: True, node: 11, level: 8" node_number="11"> <li class="valid" valid="valid" title="valid: True, node: 12, level: 9" node_number="12"> <a class="valid" valid="valid" title="valid: True, node: 13, level: 10" node_number="13"> AFIB </a> </li> <li class="valid" valid="valid" title="valid: True, node: 14, level: 9" node_number="14"> <a class="valid" valid="valid" title="valid: True, node: 15, level: 10" node_number="15"> DVT/PE </a> </li> <li class="valid" valid="valid" title="valid: True, node: 16, level: 9" node_number="16"> <a class="valid" valid="valid" title="valid: True, node: 17, level: 10" node_number="17"> CAD </a> </li> </ul> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 18, level: 6" node_number="18"> <div class="valid" valid="valid" title="valid: True, node: 19, level: 7" node_number="19"> <div class="valid" valid="valid" title="valid: True, node: 20, level: 8" node_number="20"> <h3 class="valid" valid="valid" title="valid: True, node: 21, level: 9" node_number="21">You can help lower your risk of CAD-related events</h3> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 22, level: 7" node_number="22"> What is CAD? <p class="valid" valid="valid" title="valid: True, node: 23, level: 8" node_number="23">Coronary artery disease, or CAD, is a heart condition that may be more common than you think.</p> <div class="valid" valid="valid" title="valid: True, node: 24, level: 8" node_number="24"> <div class="valid" valid="valid" title="valid: True, node: 25, level: 9" node_number="25"> <p class="valid" valid="valid" title="valid: True, node: 26, level: 10" node_number="26">More than 370,000 PEOPLE DIE FROM CAD, the most common heart disease in the US, each year.</p> </div> <div class="valid" valid="valid" title="valid: True, node: 27, level: 9" node_number="27"> <p class="valid" valid="valid" title="valid: True, node: 28, level: 10" node_number="28">Up to 8.5 MILLION PEOPLE ARE AFFECTED BY PAD, and about 75% are not even aware of it.</p> </div> </div> <p class="valid" valid="valid" title="valid: True, node: 29, level: 8" node_number="29">Simply put, CAD is the hardening of arteries, usually caused by the buildup of plaque, around the heart, and there are a number of risk factors that contribute to it. &#8220;High blood pressure, high cholesterol, diabetes, smoking, and obesity are the major modifiable risk factors, and the risk factors you can't control include age and family history," says Dr. Sanjum Sethi, a cardiologist at Columbia University Medical Center.</p> <p class="valid" valid="valid" title="valid: True, node: 30, level: 8" node_number="30">Peripheral artery disease (PAD) occurs when arteries away from the heart, including those that deliver blood to the arms and legs, harden in a similar fashion to CAD, and there is a strong correlation between the two.</p> <div class="valid" valid="valid" title="valid: True, node: 31, level: 8" node_number="31"> <p class="valid" valid="valid" title="valid: True, node: 32, level: 9" node_number="32">&#8220;When somebody is at risk for depositing plaques, they deposit plaques in more than one area of the body. So often, if you have CAD, you are at increased risk for having PAD."</p> <p class="valid" valid="valid" title="valid: True, node: 33, level: 9" node_number="33">Dr. Sanjum Sethi</p> </div> <div class="valid" valid="valid" title="valid: True, node: 34, level: 8" node_number="34"> Learn About CAD and PAD <p class="valid" valid="valid" title="valid: True, node: 35, level: 9" node_number="35">In people with CAD or PAD, cholesterol, white blood cells, and other substances build up inside damaged artery walls, forming plaque. It's similar to the sludge inside of pipes. As you can imagine, this makes it difficult for blood to travel through these arteries, reducing essential blood flow to the heart. In CAD, this can cause symptoms like chest pain, shortness of breath, and even blood clots. &#8220;When I talk to patients, I'm very interested in how much functional activity they are able to do, such as walking around and other daily activities, without getting tired or winded. This is important in terms of understanding whether they have [the] disease and how significant it is," says Dr. Sethi.</p> </div> <div class="valid" valid="valid" title="valid: True, node: 36, level: 8" node_number="36"> <div class="valid" valid="valid" title="valid: True, node: 37, level: 9" node_number="37"><h2 class="valid" valid="valid" title="valid: True, node: 38, level: 10" node_number="38">CAD and PAD risk factors include</h2></div> <div class="valid" valid="valid" title="valid: True, node: 39, level: 9" node_number="39"> <div class="valid" valid="valid" title="valid: True, node: 40, level: 10" node_number="40"> <h3 class="valid" valid="valid" title="valid: True, node: 41, level: 11" node_number="41">SMOKING</h3> </div> <div class="valid" valid="valid" title="valid: True, node: 42, level: 10" node_number="42"> <h3 class="valid" valid="valid" title="valid: True, node: 43, level: 11" node_number="43">DIABETES</h3> </div> <div class="valid" valid="valid" title="valid: True, node: 44, level: 10" node_number="44"> <h3 class="valid" valid="valid" title="valid: True, node: 45, level: 11" node_number="45">HIGH CHOLESTEROL</h3> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 46, level: 9" node_number="46"> <div class="valid" valid="valid" title="valid: True, node: 47, level: 10" node_number="47"> <h3 class="valid" valid="valid" title="valid: True, node: 48, level: 11" node_number="48">HIGH BLOOD PRESSURE</h3> </div> <div class="valid" valid="valid" title="valid: True, node: 49, level: 10" node_number="49"> <h3 class="valid" valid="valid" title="valid: True, node: 50, level: 11" node_number="50">FAMILY HISTORY OF HEART DISEASE</h3> </div> <div class="valid" valid="valid" title="valid: True, node: 51, level: 10" node_number="51"> <h3 class="valid" valid="valid" title="valid: True, node: 52, level: 11" node_number="52">BEING OVERWEIGHT</h3> </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 53, level: 7" node_number="53"> <div class="valid" valid="valid" title="valid: True, node: 54, level: 8" node_number="54"> Symptoms <p class="valid" valid="valid" title="valid: True, node: 55, level: 9" node_number="55">Blood clots are a cause for concern for people with CAD or PAD because there is a risk that plaques will rupture inside the artery. Once this happens, your body's blood clotting response is triggered, and a clot forms around the ruptured plaque. For people with CAD, this blood clot can block blood flow to your heart, causing a heart attack, or break off and travel to your brain, causing a stroke. With PAD, a blood clot can form in an artery of the limbs, such as the leg, causing pain or a more serious event that requires amputation. These are serious consequences&#8212;some of which can lead to death&#8212;all of which can be avoided.</p> </div> <div class="valid" valid="valid" title="valid: True, node: 56, level: 8" node_number="56"> <p class="valid" valid="valid" title="valid: True, node: 57, level: 9" node_number="57">If you've been diagnosed with CAD or PAD or a had a stent procedure or bypass surgery, keep an eye out for symptoms:</p> <div class="valid" valid="valid" title="valid: True, node: 58, level: 9" node_number="58"> <div class="valid" valid="valid" title="valid: True, node: 59, level: 10" node_number="59"> <h4 class="valid" valid="valid" title="valid: True, node: 60, level: 11" node_number="60">CAD</h4> <ul class="valid" valid="valid" title="valid: True, node: 61, level: 11" node_number="61"> <li class="valid" valid="valid" title="valid: True, node: 62, level: 12" node_number="62">Chest pain</li> <li class="valid" valid="valid" title="valid: True, node: 63, level: 12" node_number="63">Shortness of breath</li> <li class="valid" valid="valid" title="valid: True, node: 64, level: 12" node_number="64">Heart fluttering, pounding or racing</li> <li class="valid" valid="valid" title="valid: True, node: 65, level: 12" node_number="65">Fatigue</li> <li class="valid" valid="valid" title="valid: True, node: 66, level: 12" node_number="66">Nausea or vomiting</li> </ul> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 67, level: 9" node_number="67"> <div class="valid" valid="valid" title="valid: True, node: 68, level: 10" node_number="68"> <h4 class="valid" valid="valid" title="valid: True, node: 69, level: 11" node_number="69">PAD</h4> <ul class="valid" valid="valid" title="valid: True, node: 70, level: 11" node_number="70"> <li class="valid" valid="valid" title="valid: True, node: 71, level: 12" node_number="71">Leg cramping, numbness, weakness, or coldness</li> <li class="valid" valid="valid" title="valid: True, node: 72, level: 12" node_number="72">Sores on toes, or legs</li> <li class="valid" valid="valid" title="valid: True, node: 73, level: 12" node_number="73">Change in hair/nail growth on legs or feet</li> <li class="valid" valid="valid" title="valid: True, node: 74, level: 12" node_number="74">Change in color or shine on skin of legs</li> <li class="valid" valid="valid" title="valid: True, node: 75, level: 12" node_number="75">No pulse or weak pulse in legs or feet</li> <li class="valid" valid="valid" title="valid: True, node: 76, level: 12" node_number="76">Erectile dysfunction in men</li> </ul> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 77, level: 9" node_number="77"> <p class="valid" valid="valid" title="valid: True, node: 78, level: 10" node_number="78">These risk factors cause damage and inflammation to the artery wall, increasing the chance of a blood clot</p> </div> <p class="valid" valid="valid" title="valid: True, node: 79, level: 9" node_number="79">Even if you don't experience symptoms, you can still be at risk&#8212;especially if you've been diagnosed with CAD, had a heart attack, or received a stent or bypass procedure. </p> </div> <div class="valid" valid="valid" title="valid: True, node: 80, level: 8" node_number="80"> <p class="valid" valid="valid" title="valid: True, node: 81, level: 9" node_number="81">&#8220;I use all of the risk factors to understand what a patient's risk is, and based on that, we come up with a treatment plan&#8212;whether it be medical, surgical, or invasive&#8212;that is tailored to them."</p> <p class="valid" valid="valid" title="valid: True, node: 82, level: 9" node_number="82">Dr. Sanjum Sethi</p> </div> <div class="valid" valid="valid" title="valid: True, node: 83, level: 8" node_number="83"> Understanding Treatments and Procedures <p class="valid" valid="valid" title="valid: True, node: 84, level: 9" node_number="84">There are several procedures that can help restore blood flow in a blocked artery. These include angioplasty, stent implantation, and coronary artery bypass graft surgery (CABG). Angioplasty opens a blocked artery by inflating a tiny balloon inside the blockage. Stent implantation permanently props open a blocked artery with a tiny wire mesh tube that is placed during an angioplasty. CABG reroutes blood around a completely blocked artery using a blood vessel from another part of your body. These procedures may be life-saving, but they do not fix you for good, and you are still at risk even if a heart attack or stent procedure happened a while ago.</p> <p class="valid" valid="valid" title="valid: True, node: 85, level: 9" node_number="85">Once you have an event like a heart attack or stent procedure, your doctor will likely put you on a treatment plan that includes several medications. These medications may include anticoagulants, or blood thinners, which help prevent blood clots from forming. Another medication is antiplatelets that, like aspirin, keep platelets from sticking together. Many people take aspirin as a blood thinner, but it may not be enough. A large study of almost 40,000 people showed that even though more than half were taking aspirin, the number of heart attacks, strokes, and cardiovascular deaths more than doubled over a two-year period.*</p> <p class="valid" valid="valid" title="valid: True, node: 86, level: 9" node_number="86">*According to data from the REACH Registry.</p> </div> <div class="valid" valid="valid" title="valid: True, node: 87, level: 8" node_number="87"> Help Reduce Your Risk of Cardiovascular Events <p class="valid" valid="valid" title="valid: True, node: 88, level: 9" node_number="88">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 89, level: 10" node_number="89">&#174;</sup> 2.5 mg twice daily, when taken with low-dose aspirin,<sup class="valid" valid="valid" title="valid: True, node: 90, level: 10" node_number="90">&#8224;</sup> is proven to help further reduce the risk of blood clots that can cause heart attack, stroke, or cardiovascular death in people with chronic CAD or PAD. In a clinical trial, almost 96% of people with chronic CAD or PAD taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 91, level: 10" node_number="91">&#174;</sup> did not have a cardiovascular event.<sup class="valid" valid="valid" title="valid: True, node: 92, level: 10" node_number="92">&#8225;</sup></p> <p class="valid" valid="valid" title="valid: True, node: 93, level: 9" node_number="93"><sup class="valid" valid="valid" title="valid: True, node: 94, level: 10" node_number="94">&#8224;</sup>Low-dose aspirin = 75-mg-100-mg aspirin tablet.</p> <p class="valid" valid="valid" title="valid: True, node: 95, level: 9" node_number="95"><sup class="valid" valid="valid" title="valid: True, node: 96, level: 10" node_number="96">&#8225;</sup>Rate of first event (heart attack, stroke, cardiovascular death) was 4.1% for people taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 97, level: 10" node_number="97">&#174;</sup> plus aspirin vs. 5.4% for aspirin alone. Patients were followed for an average of 23 months. </p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 98, level: 7" node_number="98"> <div class="valid" valid="valid" title="valid: True, node: 99, level: 8" node_number="99"> <div class="valid" valid="valid" title="valid: True, node: 100, level: 9" node_number="100"> <div class="valid" valid="valid" title="valid: True, node: 101, level: 10" node_number="101"> <div class="valid" valid="valid" title="valid: True, node: 102, level: 11" node_number="102"> <h2 class="valid" valid="valid" title="valid: True, node: 103, level: 12" node_number="103">What do I need to know about CAD?</h2> <p class="valid" valid="valid" title="valid: True, node: 104, level: 12" node_number="104">CAD (coronary artery disease) is a condition resulting from atherosclerosis, or a hardening of the arteries, which is caused by the buildup of plaque in the arteries that supply blood to the heart&#8212;like sludge on the inside of pipes. These plaques can rupture, causing a blood clot to form.</p> <p class="valid" valid="valid" title="valid: True, node: 105, level: 12" node_number="105">If you've been diagnosed with CAD, had a heart attack, or had a stent or bypass procedure, you may still have an underlying risk for blood clots that can cause a cardiovascular event. </p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 106, level: 10" node_number="106"> <div class="valid" valid="valid" title="valid: True, node: 107, level: 11" node_number="107"> <h2 class="valid" valid="valid" title="valid: True, node: 108, level: 12" node_number="108">What are the consequences of CAD?</h2> <p class="valid" valid="valid" title="valid: True, node: 109, level: 12" node_number="109">The risk for blood clots in people with CAD is high, and these blood clots can break free and travel through the arteries, which can lead to serious cardiovascular events like stroke and heart attack.</p> <p class="valid" valid="valid" title="valid: True, node: 110, level: 12" node_number="110">Even if you had a stent procedure, bypass surgery, or a heart attack a while ago, you're taking medication, and you're trying to eat right and stay active, the risk for a cardiovascular event still increases over time.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 111, level: 10" node_number="111"> <div class="valid" valid="valid" title="valid: True, node: 112, level: 11" node_number="112"> <h2 class="valid" valid="valid" title="valid: True, node: 113, level: 12" node_number="113">What is PAD, and how is it related to CAD?</h2> <p class="valid" valid="valid" title="valid: True, node: 114, level: 12" node_number="114">For people with CAD, a blood clot occurs in the arteries that supply blood to the heart, and for people with peripheral artery disease (PAD), a blood clot occurs in the arteries of the limbs&#8212;usually the legs.</p> <p class="valid" valid="valid" title="valid: True, node: 115, level: 12" node_number="115">Both CAD and PAD are the result of hardening of the arteries caused by damage or inflammation of the artery wall due to certain health conditions or risk factors, including diabetes, high blood pressure, high cholesterol, smoking, or a family history of heart disease.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 116, level: 10" node_number="116"> <div class="valid" valid="valid" title="valid: True, node: 117, level: 11" node_number="117"> <h2 class="valid" valid="valid" title="valid: True, node: 118, level: 12" node_number="118">Can I have both CAD and PAD?</h2> <p class="valid" valid="valid" title="valid: True, node: 119, level: 12" node_number="119">It is common for people with CAD to also have PAD. In addition to CAD and PAD sharing similar risk factors, people who have both CAD and PAD have an even higher risk for cardiovascular events than people with CAD or PAD alone, so it's important to ask your doctor about an ankle-brachial index screening test for PAD.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 120, level: 10" node_number="120"> <div class="valid" valid="valid" title="valid: True, node: 121, level: 11" node_number="121"> <h2 class="valid" valid="valid" title="valid: True, node: 122, level: 12" node_number="122">What can I do to lower my risk of developing CAD or PAD?</h2> <p class="valid" valid="valid" title="valid: True, node: 123, level: 12" node_number="123">There are simple things you can do like exercising, maintaining a healthy weight, eating healthy, and managing stress levels. If you are a smoker, quit smoking. And if you have other conditions like diabetes or high cholesterol, manage those as well.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 124, level: 10" node_number="124"> <div class="valid" valid="valid" title="valid: True, node: 125, level: 11" node_number="125"> <h2 class="valid" valid="valid" title="valid: True, node: 126, level: 12" node_number="126">What are the treatments for CAD and PAD?</h2> <p class="valid" valid="valid" title="valid: True, node: 127, level: 12" node_number="127">Some people get a stent placed in their artery or have bypass surgery, while others take blood thinners in addition to a stent.</p> <p class="valid" valid="valid" title="valid: True, node: 128, level: 12" node_number="128">Some blood thinners, like aspirin, keep platelets from sticking together, while others slow down the blood's clotting process&#8212;all to reduce the chance of blood clots that can cause heart attack or stroke.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 129, level: 10" node_number="129"> <div class="valid" valid="valid" title="valid: True, node: 130, level: 11" node_number="130"> <h2 class="valid" valid="valid" title="valid: True, node: 131, level: 12" node_number="131">What treatment is best for me? And is aspirin alone enough?</h2> <p class="valid" valid="valid" title="valid: True, node: 132, level: 12" node_number="132">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 133, level: 13" node_number="133">&#174;</sup>, when taken with low-dose aspirin,<sup class="valid" valid="valid" title="valid: True, node: 134, level: 13" node_number="134">*</sup> is proven to help further reduce the risk of blood clots that can cause heart attack, stroke, or cardiovascular death in people with chronic CAD.</p> <p class="valid" valid="valid" title="valid: True, node: 135, level: 12" node_number="135">While aspirin can help, a recent study showed it may not be enough to manage the underlying risk of blood clots returning. In a clinical trial, almost 96% of people taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 136, level: 13" node_number="136">&#174;</sup> 2.5 mg twice daily in combination with low-dose aspirin did not have a cardiovascular event.<sup class="valid" valid="valid" title="valid: True, node: 137, level: 13" node_number="137">&#8224;</sup></p> <p class="valid" valid="valid" title="valid: True, node: 138, level: 12" node_number="138"><sup class="valid" valid="valid" title="valid: True, node: 139, level: 13" node_number="139">*</sup>Low-dose aspirin = 75-mg to 100-mg aspirin tablet.</p> <p class="valid" valid="valid" title="valid: True, node: 140, level: 12" node_number="140"><sup class="valid" valid="valid" title="valid: True, node: 141, level: 13" node_number="141">&#8224;</sup>Rate of first event (heart attack, stroke, cardiovascular death) was 4.1% for people taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 142, level: 13" node_number="142">&#174;</sup> plus aspirin vs. 5.4% for aspirin alone. Patients were followed for an average of 23 months.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 143, level: 10" node_number="143"> <div class="valid" valid="valid" title="valid: True, node: 144, level: 11" node_number="144"> <h2 class="valid" valid="valid" title="valid: True, node: 145, level: 12" node_number="145">What else can I do to help lower my risk of cardiovascular events?</h2> <p class="valid" valid="valid" title="valid: True, node: 146, level: 12" node_number="146"> CAD and PAD have serious consequences, and both conditions get worse over time. Ask for support from your loved ones to encourage healthy habits.</p> <p class="valid" valid="valid" title="valid: True, node: 147, level: 12" node_number="147">Most importantly, stay in touch with your healthcare team and take your medications as prescribed by your doctor.</p> </div> </div> </div> </div> <p class="valid" valid="valid" title="valid: True, node: 148, level: 8" node_number="148">If you are one of the millions who have CAD, you know how important it is to take preventative measures to remain as healthy as possible. Remember, even if you are eating healthy, staying active, and your event occurred a long time ago, you are still at risk. Talk to your doctor to better understand your risk for blood clots that can lead to a cardiovascular event and learn which treatments are best for you.</p> <div class="valid" valid="valid" title="valid: True, node: 149, level: 8" node_number="149"> <div class="valid" valid="valid" title="valid: True, node: 150, level: 9" node_number="150"> <p class="valid" valid="valid" title="valid: True, node: 151, level: 10" node_number="151">WHILE ASPIRIN CAN HELP, IT MAY NOT BE ENOUGH. In a large study that included people with CAD or PAD, there was a more than 2X INCREASE IN HEART ATTACKS, STROKE, AND CARDIOVASCULAR DEATH with or without aspirin.* Talk to your doctor about other treatment options to lower your risk for stroke.</p> <p class="valid" valid="valid" title="valid: True, node: 152, level: 10" node_number="152">*According to data from the REACH Registry.</p> <p class="valid" valid="valid" title="valid: True, node: 153, level: 10" node_number="153"><span class="valid" valid="valid" title="valid: True, node: 154, level: 11" node_number="154">In a clinical trial, almost 96% of people<sup class="valid" valid="valid" title="valid: True, node: 155, level: 12" node_number="155">&#8224;</sup> with chronic CAD or PAD taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 156, level: 12" node_number="156">&#174;</sup> 2.5 mg twice daily in combination with low-dose aspirin<sup class="valid" valid="valid" title="valid: True, node: 157, level: 12" node_number="157">&#167;</sup> once daily did not have a heart attack, stroke, or die from a cardiovascular event.</span></p> <p class="valid" valid="valid" title="valid: True, node: 158, level: 10" node_number="158"><sup class="valid" valid="valid" title="valid: True, node: 159, level: 11" node_number="159">&#8224;</sup>The rate of the first event was 4.1% for people taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 160, level: 11" node_number="160">&#174;</sup> plus aspirin vs 5.4% for aspirin alone. Patients were followed for an average of 23 months. <sup class="valid" valid="valid" title="valid: True, node: 161, level: 11" node_number="161">&#167;</sup>Low-dose aspirin = 75-mg-100-mg aspirin tablet.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 162, level: 8" node_number="162"> <div class="valid" valid="valid" title="valid: True, node: 163, level: 9" node_number="163"><p class="valid" valid="valid" title="valid: True, node: 164, level: 10" node_number="164">YOUR DOCTOR IS ALWAYS YOUR BEST RESOURCE. He or she knows your situation best and can help you determine a treatment plan.</p></div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 165, level: 7" node_number="165"> <div class="valid" valid="valid" title="valid: True, node: 166, level: 8" node_number="166"> <h1 class="valid" valid="valid" title="valid: True, node: 167, level: 9" node_number="167">Find out more about how to help reduce your risk of cardiovascular events with XARELTO<sup class="valid" valid="valid" title="valid: True, node: 168, level: 10" node_number="168">&#174;</sup></h1> Learn More </div> </div> </div> </div> </div> </div><div class="valid" valid="valid" title="valid: True, node: 169, level: 3" node_number="169"><div class="valid" valid="valid" title="valid: True, node: 170, level: 4" node_number="170"> <div class="valid" valid="valid" title="valid: True, node: 171, level: 5" node_number="171"> <div class="valid" valid="valid" title="valid: True, node: 172, level: 6" node_number="172"> <div class="valid" valid="valid" title="valid: True, node: 173, level: 7" node_number="173"> <div class="valid" valid="valid" title="valid: True, node: 174, level: 8" node_number="174"> <div class="valid" valid="valid" title="valid: True, node: 175, level: 9" node_number="175"> <div class="valid" valid="valid" title="valid: True, node: 176, level: 10" node_number="176"> WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 177, level: 11" node_number="177">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 178, level: 10" node_number="178"> <p class="valid" valid="valid" title="valid: True, node: 179, level: 11" node_number="179">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 180, level: 12" node_number="180">&#174;</sup> is a prescription medicine used to:</p> <ul class="valid" valid="valid" title="valid: True, node: 181, level: 11" node_number="181"> <li class="valid" valid="valid" title="valid: True, node: 182, level: 12" node_number="182"> reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body </li> <li class="valid" valid="valid" title="valid: True, node: 183, level: 12" node_number="183"> treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE) </li> <li class="valid" valid="valid" title="valid: True, node: 184, level: 12" node_number="184"> reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 185, level: 11" node_number="185">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 186, level: 12" node_number="186">&#174;</sup> is used with low dose aspirin to:</p> <ul class="valid" valid="valid" title="valid: True, node: 187, level: 11" node_number="187"> <li class="valid" valid="valid" title="valid: True, node: 188, level: 12" node_number="188"> reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 189, level: 11" node_number="189">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 190, level: 12" node_number="190">&#174;</sup> is safe and effective in children.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 191, level: 9" node_number="191"> <div class="valid" valid="valid" title="valid: True, node: 192, level: 10" node_number="192">WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 193, level: 11" node_number="193">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 194, level: 10" node_number="194"> <p class="valid" valid="valid" title="valid: True, node: 195, level: 11" node_number="195">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 196, level: 12" node_number="196">&#174;</sup> is a prescription medicine used to:</p> <ul class="valid" valid="valid" title="valid: True, node: 197, level: 11" node_number="197"> <li class="valid" valid="valid" title="valid: True, node: 198, level: 12" node_number="198">reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 199, level: 11" node_number="199">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 200, level: 12" node_number="200">&#174;</sup> is safe and effective in children.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 201, level: 9" node_number="201"> <div class="valid" valid="valid" title="valid: True, node: 202, level: 10" node_number="202">WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 203, level: 11" node_number="203">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 204, level: 10" node_number="204"> <p class="valid" valid="valid" title="valid: True, node: 205, level: 11" node_number="205">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 206, level: 12" node_number="206">&#174;</sup> is a prescription medicine used to:</p> <ul class="valid" valid="valid" title="valid: True, node: 207, level: 11" node_number="207"> <li class="valid" valid="valid" title="valid: True, node: 208, level: 12" node_number="208">treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE)</li> <li class="valid" valid="valid" title="valid: True, node: 209, level: 12" node_number="209">reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 210, level: 11" node_number="210">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 211, level: 12" node_number="211">&#174;</sup> is safe and effective in children.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 212, level: 9" node_number="212"> <div class="valid" valid="valid" title="valid: True, node: 213, level: 10" node_number="213">WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 214, level: 11" node_number="214">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 215, level: 10" node_number="215"> <p class="valid" valid="valid" title="valid: True, node: 216, level: 11" node_number="216">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 217, level: 12" node_number="217">&#174;</sup> is a prescription medicine used with low dose aspirin to:</p> <ul class="valid" valid="valid" title="valid: True, node: 218, level: 11" node_number="218"> <li class="valid" valid="valid" title="valid: True, node: 219, level: 12" node_number="219">reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 220, level: 11" node_number="220">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 221, level: 12" node_number="221">&#174;</sup> is safe and effective in children.</p> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 222, level: 8" node_number="222"> <h3 class="valid" valid="valid" title="valid: True, node: 223, level: 9" node_number="223">IMPORTANT SAFETY INFORMATION</h3> <p class="valid" valid="valid" title="valid: True, node: 224, level: 9" node_number="224">WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT XARELTO<sup class="valid" valid="valid" title="valid: True, node: 225, level: 10" node_number="225">&#174;</sup>?</p> <p class="valid" valid="valid" title="valid: True, node: 226, level: 9" node_number="226"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 227, level: 10" node_number="227">&#174;</sup> may cause serious side effects, including: </p> <ul class="valid" valid="valid" title="valid: True, node: 228, level: 9" node_number="228"> <li class="valid" valid="valid" title="valid: True, node: 229, level: 10" node_number="229"> Increased risk of blood clots if you stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 230, level: 11" node_number="230">&#174;</sup>. People with atrial fibrillation (an irregular heart beat) that is not caused by a heart valve problem (nonvalvular) are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a stroke, or to other parts of the body. XARELTO<sup class="valid" valid="valid" title="valid: True, node: 231, level: 11" node_number="231">&#174;</sup> lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 232, level: 11" node_number="232">&#174;</sup>, you may have increased risk of forming a clot in your blood. </li> <li class="valid" valid="valid" title="valid: True, node: 233, level: 10" node_number="233"> Do not stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 234, level: 11" node_number="234">&#174;</sup> without talking to the doctor who prescribes it for you. Stopping XARELTO<sup class="valid" valid="valid" title="valid: True, node: 235, level: 11" node_number="235">&#174;</sup> increases your risk of having a stroke. If you have to stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 236, level: 11" node_number="236">&#174;</sup>, your doctor may prescribe another blood thinner medicine to prevent a blood clot from forming. </li> <li class="valid" valid="valid" title="valid: True, node: 237, level: 10" node_number="237"> Increased risk of bleeding. XARELTO<sup class="valid" valid="valid" title="valid: True, node: 238, level: 11" node_number="238">&#174;</sup> can cause bleeding which can be serious, and may lead to death. This is because XARELTO<sup class="valid" valid="valid" title="valid: True, node: 239, level: 11" node_number="239">&#174;</sup> is a blood thinner medicine (anticoagulant) that lowers blood clotting. During treatment with XARELTO<sup class="valid" valid="valid" title="valid: True, node: 240, level: 11" node_number="240">&#174;</sup> you are likely to bruise more easily, and it may take longer for bleeding to stop. You may be at higher risk of bleeding if you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 241, level: 11" node_number="241">&#174;</sup> and have certain other medical problems. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 242, level: 9" node_number="242"> You may have a higher risk of bleeding if you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 243, level: 10" node_number="243">&#174;</sup> and take other medicines that increase your risk of bleeding, including: </p> <ul class="valid" valid="valid" title="valid: True, node: 244, level: 9" node_number="244"> <li class="valid" valid="valid" title="valid: True, node: 245, level: 10" node_number="245">Aspirin or aspirin-containing products</li> <li class="valid" valid="valid" title="valid: True, node: 246, level: 10" node_number="246">Long-term (chronic) use of non-steroidal anti-inflammatory drugs (NSAIDs)</li> <li class="valid" valid="valid" title="valid: True, node: 247, level: 10" node_number="247">Warfarin sodium (Coumadin<sup class="valid" valid="valid" title="valid: True, node: 248, level: 11" node_number="248">&#174;</sup>, Jantoven<sup class="valid" valid="valid" title="valid: True, node: 249, level: 11" node_number="249">&#174;</sup>)</li> <li class="valid" valid="valid" title="valid: True, node: 250, level: 10" node_number="250">Any medicine that contains heparin</li> <li class="valid" valid="valid" title="valid: True, node: 251, level: 10" node_number="251">Clopidogrel (Plavix<sup class="valid" valid="valid" title="valid: True, node: 252, level: 11" node_number="252">&#174;</sup>)</li> <li class="valid" valid="valid" title="valid: True, node: 253, level: 10" node_number="253">Selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)</li> <li class="valid" valid="valid" title="valid: True, node: 254, level: 10" node_number="254">Other medicines to prevent or treat blood clots</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 255, level: 9" node_number="255"> Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above. </p> <p class="valid" valid="valid" title="valid: True, node: 256, level: 9" node_number="256"> Call your doctor or get medical help right away if you develop any of these signs or symptoms of bleeding: </p> <ul class="valid" valid="valid" title="valid: True, node: 257, level: 9" node_number="257"> <li class="valid" valid="valid" title="valid: True, node: 258, level: 10" node_number="258">Unexpected bleeding or bleeding that lasts a long time, such as:</li> </ul> <ul class="valid" valid="valid" title="valid: True, node: 259, level: 9" node_number="259"> <li class="valid" valid="valid" title="valid: True, node: 260, level: 10" node_number="260">Nosebleeds that happen often</li> <li class="valid" valid="valid" title="valid: True, node: 261, level: 10" node_number="261">Unusual bleeding from gums</li> <li class="valid" valid="valid" title="valid: True, node: 262, level: 10" node_number="262">Menstrual bleeding that is heavier than normal, or vaginal bleeding</li> </ul> <ul class="valid" valid="valid" title="valid: True, node: 263, level: 9" node_number="263"> <li class="valid" valid="valid" title="valid: True, node: 264, level: 10" node_number="264">Bleeding that is severe or you cannot control</li> <li class="valid" valid="valid" title="valid: True, node: 265, level: 10" node_number="265">Red, pink, or brown urine</li> <li class="valid" valid="valid" title="valid: True, node: 266, level: 10" node_number="266">Bright red or black stools (looks like tar)</li> <li class="valid" valid="valid" title="valid: True, node: 267, level: 10" node_number="267">Cough up blood or blood clots</li> <li class="valid" valid="valid" title="valid: True, node: 268, level: 10" node_number="268">Vomit blood or your vomit looks like "coffee grounds"</li> <li class="valid" valid="valid" title="valid: True, node: 269, level: 10" node_number="269">Headaches, feeling dizzy or weak</li> <li class="valid" valid="valid" title="valid: True, node: 270, level: 10" node_number="270">Pain, swelling, or new drainage at wound sites</li> </ul> <li class="valid" valid="valid" title="valid: True, node: 271, level: 9" node_number="271"> Spinal or epidural blood clots (hematoma).&#160;People who take a blood thinner medicine (anticoagulant) like XARELTO<sup class="valid" valid="valid" title="valid: True, node: 272, level: 10" node_number="272">&#174;</sup>, and have medicine injected into their spinal and epidural area, or have a spinal puncture, have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis). Your risk of developing a spinal or epidural blood clot is higher if: <ul class="valid" valid="valid" title="valid: True, node: 273, level: 10" node_number="273"> <li class="valid" valid="valid" title="valid: True, node: 274, level: 11" node_number="274"> A thin tube called an epidural catheter is placed in your back to give you certain medicine </li> <li class="valid" valid="valid" title="valid: True, node: 275, level: 11" node_number="275"> You take NSAIDs or a medicine to prevent blood from clotting </li> <li class="valid" valid="valid" title="valid: True, node: 276, level: 11" node_number="276"> You have a history of difficult or repeated epidural or spinal punctures </li> <li class="valid" valid="valid" title="valid: True, node: 277, level: 11" node_number="277"> You have a history of problems with your spine or have had surgery on your spine </li> </ul> </li> <p class="valid" valid="valid" title="valid: True, node: 278, level: 9" node_number="278"> If you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 279, level: 10" node_number="279">&#174;</sup> and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots. Tell your doctor right away if you have back pain, tingling, numbness, muscle weakness (especially in your legs and feet), or loss of control of the bowels or bladder (incontinence). </p> <p class="valid" valid="valid" title="valid: True, node: 280, level: 9" node_number="280"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 281, level: 10" node_number="281">&#174;</sup> is not for use in people with artificial heart valves. </p> <p class="valid" valid="valid" title="valid: True, node: 282, level: 9" node_number="282"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 283, level: 10" node_number="283">&#174;</sup> is not for use in people with antiphospholipid syndrome (APS), especially with positive triple antibody testing. </p> <p class="valid" valid="valid" title="valid: True, node: 284, level: 9" node_number="284"> &#8203;&#8203;Do not take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 285, level: 10" node_number="285">&#174;</sup> if you: </p> <ul class="valid" valid="valid" title="valid: True, node: 286, level: 9" node_number="286"> <li class="valid" valid="valid" title="valid: True, node: 287, level: 10" node_number="287"> Currently have certain types of abnormal bleeding. Talk to your doctor before taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 288, level: 11" node_number="288">&#174;</sup> if you currently have unusual bleeding. </li> <li class="valid" valid="valid" title="valid: True, node: 289, level: 10" node_number="289"> Are allergic to rivaroxaban or any of the ingredients of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 290, level: 11" node_number="290">&#174;</sup>. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 291, level: 9" node_number="291"> &#8203;&#8203;Before taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 292, level: 10" node_number="292">&#174;</sup>, tell your doctor about all your medical conditions, including if you: </p> <ul class="valid" valid="valid" title="valid: True, node: 293, level: 9" node_number="293"> <li class="valid" valid="valid" title="valid: True, node: 294, level: 10" node_number="294"> Have ever had bleeding problems </li> <li class="valid" valid="valid" title="valid: True, node: 295, level: 10" node_number="295"> Have liver or kidney problems </li> <li class="valid" valid="valid" title="valid: True, node: 296, level: 10" node_number="296"> Have antiphospholipid syndrome (APS) </li> <li class="valid" valid="valid" title="valid: True, node: 297, level: 10" node_number="297"> Are pregnant or plan to become pregnant. It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 298, level: 11" node_number="298">&#174;</sup> will harm your unborn baby. <ul class="valid" valid="valid" title="valid: True, node: 299, level: 11" node_number="299"> <li class="valid" valid="valid" title="valid: True, node: 300, level: 12" node_number="300"> Tell your doctor right away if you become pregnant during treatment with XARELTO<sup class="valid" valid="valid" title="valid: True, node: 301, level: 13" node_number="301">&#174;</sup>. Taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 302, level: 13" node_number="302">&#174;</sup> while you are pregnant may increase the risk of bleeding in you or in your unborn baby. </li> <li class="valid" valid="valid" title="valid: True, node: 303, level: 12" node_number="303"> If you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 304, level: 13" node_number="304">&#174;</sup> during pregnancy, tell your doctor right away if you have any signs or symptoms of bleeding or blood loss.&#160;See &#8220;What is the most important information I should know about XARELTO<sup class="valid" valid="valid" title="valid: True, node: 305, level: 13" node_number="305">&#174;</sup>?&#8221; for signs and symptoms of bleeding. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 306, level: 10" node_number="306"> Are breastfeeding or plan to breastfeed. XARELTO<sup class="valid" valid="valid" title="valid: True, node: 307, level: 11" node_number="307">&#174;</sup> may pass into your breast milk. Talk to your doctor about the best way to feed your baby during treatment with XARELTO<sup class="valid" valid="valid" title="valid: True, node: 308, level: 11" node_number="308">&#174;</sup>. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 309, level: 9" node_number="309"> Tell all of your doctors and dentists that you are taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 310, level: 10" node_number="310">&#174;</sup>. They should talk to the doctor who prescribed XARELTO<sup class="valid" valid="valid" title="valid: True, node: 311, level: 10" node_number="311">&#174;</sup> for you before you have any surgery, medical or dental procedure. </p> <p class="valid" valid="valid" title="valid: True, node: 312, level: 9" node_number="312"> Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements<b class="valid" valid="valid" title="valid: True, node: 313, level: 10" node_number="313">. </b> </p> <p class="valid" valid="valid" title="valid: True, node: 314, level: 9" node_number="314"> Some of your other medicines may affect the way XARELTO<sup class="valid" valid="valid" title="valid: True, node: 315, level: 10" node_number="315">&#174;</sup> works, causing side effects. Certain medicines may increase your risk of bleeding. See &#8220;What is the most important information I should know about XARELTO<sup class="valid" valid="valid" title="valid: True, node: 316, level: 10" node_number="316">&#174;</sup>?&#8221; </p> <p class="valid" valid="valid" title="valid: True, node: 317, level: 9" node_number="317"> HOW SHOULD I TAKE XARELTO<sup class="valid" valid="valid" title="valid: True, node: 318, level: 10" node_number="318">&#174;</sup>? </p> <ul class="valid" valid="valid" title="valid: True, node: 319, level: 9" node_number="319"> <li class="valid" valid="valid" title="valid: True, node: 320, level: 10" node_number="320"> Take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 321, level: 11" node_number="321">&#174;</sup> exactly as prescribed by your doctor. </li> <li class="valid" valid="valid" title="valid: True, node: 322, level: 10" node_number="322"> Do not change your dose or stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 323, level: 11" node_number="323">&#174;</sup> unless your doctor tells you to. Your doctor may change your dose if needed. </li> <li class="valid" valid="valid" title="valid: True, node: 324, level: 10" node_number="324"> Your doctor will decide how long you should take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 325, level: 11" node_number="325">&#174;</sup>. </li> <li class="valid" valid="valid" title="valid: True, node: 326, level: 10" node_number="326"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 327, level: 11" node_number="327">&#174;</sup> may need to be stopped for one or more days before any surgery or medical or dental procedure. Your doctor will tell you when to stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 328, level: 11" node_number="328">&#174;</sup> and when to start taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 329, level: 11" node_number="329">&#174;</sup> again after your surgery or procedure. </li> <li class="valid" valid="valid" title="valid: True, node: 330, level: 10" node_number="330"> If you need to stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 331, level: 11" node_number="331">&#174;</sup> for any reason, talk to the doctor who prescribed XARELTO<sup class="valid" valid="valid" title="valid: True, node: 332, level: 11" node_number="332">&#174;</sup> to you to find out when you should stop taking it. Do not stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 333, level: 11" node_number="333">&#174;</sup> without first talking to the doctor who prescribes it to you. </li> <li class="valid" valid="valid" title="valid: True, node: 334, level: 10" node_number="334"> If you have difficulty swallowing XARELTO<sup class="valid" valid="valid" title="valid: True, node: 335, level: 11" node_number="335">&#174;</sup> tablets whole, talk to your doctor about other ways to take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 336, level: 11" node_number="336">&#174;</sup>. </li> <li class="valid" valid="valid" title="valid: True, node: 337, level: 10" node_number="337"> Do not run out of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 338, level: 11" node_number="338">&#174;</sup>. Refill your prescription of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 339, level: 11" node_number="339">&#174;</sup> before you run out. When leaving the hospital following a hip or knee replacement, be sure that you will have XARELTO<sup class="valid" valid="valid" title="valid: True, node: 340, level: 11" node_number="340">&#174;</sup> available to avoid missing any doses. </li> <li class="valid" valid="valid" title="valid: True, node: 341, level: 10" node_number="341"> If you take too much XARELTO<sup class="valid" valid="valid" title="valid: True, node: 342, level: 11" node_number="342">&#174;</sup>, go to the nearest hospital emergency room or call your doctor right away. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 343, level: 9" node_number="343"> If you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 344, level: 10" node_number="344">&#174;</sup> for:&#8203; </p> <ul class="valid" valid="valid" title="valid: True, node: 345, level: 9" node_number="345"> <ul class="valid" valid="valid" title="valid: True, node: 346, level: 10" node_number="346"> <li class="valid" valid="valid" title="valid: True, node: 347, level: 11" node_number="347"> Atrial Fibrillation that is not caused by a heart valve problem: <ul class="valid" valid="valid" title="valid: True, node: 348, level: 12" node_number="348"> <li class="valid" valid="valid" title="valid: True, node: 349, level: 13" node_number="349"> Take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 350, level: 14" node_number="350">&#174;</sup> 1 time a day with your evening meal. </li> <li class="valid" valid="valid" title="valid: True, node: 351, level: 13" node_number="351"> If you miss a dose of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 352, level: 14" node_number="352">&#174;</sup>, take it as soon as you remember on the same day.&#160;Take your next dose at your regularly scheduled time. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 353, level: 11" node_number="353"> Blood clots in the veins of your legs or lungs: <ul class="valid" valid="valid" title="valid: True, node: 354, level: 12" node_number="354"> <li class="valid" valid="valid" title="valid: True, node: 355, level: 13" node_number="355"> Take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 356, level: 14" node_number="356">&#174;&#160;</sup>1 or 2 times a day as prescribed by your doctor. </li> <li class="valid" valid="valid" title="valid: True, node: 357, level: 13" node_number="357"> For the 10-mg dose, XARELTO<sup class="valid" valid="valid" title="valid: True, node: 358, level: 14" node_number="358">&#174;</sup> may be taken with or without food. </li> <li class="valid" valid="valid" title="valid: True, node: 359, level: 13" node_number="359"> For the 15-mg and 20-mg doses, take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 360, level: 14" node_number="360">&#174;</sup> with food at the same time each day. </li> <li class="valid" valid="valid" title="valid: True, node: 361, level: 13" node_number="361"> If you miss a dose: <ul class="valid" valid="valid" title="valid: True, node: 362, level: 14" node_number="362"> <li title="valid: False, node: 363, level: 15" node_number="363"> If you take the 15-mg dose of XARELTO<sup title="valid: False, node: 364, level: 16" node_number="364">&#174;</sup> 2 times a day (a total of 30 mg of XARELTO<sup title="valid: False, node: 365, level: 16" node_number="365">&#174;</sup> in 1 day):&#160;Take XARELTO<sup title="valid: False, node: 366, level: 16" node_number="366">&#174;</sup> as soon as you remember on the same day. You may take 2 doses at the same time to make up for the missed dose. Take your next dose at your regularly scheduled time. </li> <li title="valid: False, node: 367, level: 15" node_number="367"> If you take XARELTO<sup title="valid: False, node: 368, level: 16" node_number="368">&#174;</sup> 1 time a day: Take XARELTO<sup title="valid: False, node: 369, level: 16" node_number="369">&#174;</sup> as soon as you remember on the same day. Take your next dose at your regularly scheduled time.&#8203; </li> </ul> </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 370, level: 11" node_number="370"> Hip or knee replacement surgery: <ul class="valid" valid="valid" title="valid: True, node: 371, level: 12" node_number="371"> <li class="valid" valid="valid" title="valid: True, node: 372, level: 13" node_number="372"> Take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 373, level: 14" node_number="373">&#174;</sup> 1 time a day with or without food. </li> <li class="valid" valid="valid" title="valid: True, node: 374, level: 13" node_number="374"> If you miss a dose of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 375, level: 14" node_number="375">&#174;</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 376, level: 11" node_number="376"> Blood clots in people hospitalized for an acute illness: <ul class="valid" valid="valid" title="valid: True, node: 377, level: 12" node_number="377"> <li class="valid" valid="valid" title="valid: True, node: 378, level: 13" node_number="378"> Take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 379, level: 14" node_number="379">&#174;</sup>&#160;1&#160;time a day, with or without food, while you are in the hospital and after you are discharged as prescribed by your doctor. </li> <li class="valid" valid="valid" title="valid: True, node: 380, level: 13" node_number="380"> If you miss a dose of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 381, level: 14" node_number="381">&#174;</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 382, level: 11" node_number="382"> Reducing the risk of serious heart problems, heart attack and stroke in coronary artery&#160;disease or peripheral artery disease: <ul class="valid" valid="valid" title="valid: True, node: 383, level: 12" node_number="383"> <li class="valid" valid="valid" title="valid: True, node: 384, level: 13" node_number="384"> Take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 385, level: 14" node_number="385">&#174;</sup>&#160;2.5 mg 2&#160;times a day with or without food. </li> <li class="valid" valid="valid" title="valid: True, node: 386, level: 13" node_number="386"> If you miss a dose of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 387, level: 14" node_number="387">&#174;</sup>, take your next dose at your regularly scheduled time. </li> <li class="valid" valid="valid" title="valid: True, node: 388, level: 13" node_number="388"> Take aspirin 75 to 100 mg once daily as instructed by your doctor. </li> </ul> </li> </ul> </ul> <div class="valid" valid="valid" title="valid: True, node: 389, level: 9" node_number="389"> <p class="valid" valid="valid" title="valid: True, node: 390, level: 10" node_number="390"> WHAT ARE THE POSSIBLE SIDE EFFECTS OF <span class="valid" valid="valid" title="valid: True, node: 391, level: 11" node_number="391">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 392, level: 12" node_number="392">&#174;</sup>?</span> </p> <p class="valid" valid="valid" title="valid: True, node: 393, level: 10" node_number="393"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 394, level: 11" node_number="394">&#174;</sup> may cause serious side effects: </p> <ul class="valid" valid="valid" title="valid: True, node: 395, level: 10" node_number="395"> <li class="valid" valid="valid" title="valid: True, node: 396, level: 11" node_number="396"> See &#8220;What is the most important information I should know about XARELTO<sup class="valid" valid="valid" title="valid: True, node: 397, level: 12" node_number="397">&#174;</sup>?&#8221; </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 398, level: 10" node_number="398"> The most common side effect of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 399, level: 11" node_number="399">&#174;</sup> was bleeding. </p> <p class="valid" valid="valid" title="valid: True, node: 400, level: 10" node_number="400"> Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Janssen Pharmaceuticals, Inc., at 1-800-JANSSEN (1-800-526-7736). </p> <p class="valid" valid="valid" title="valid: True, node: 401, level: 10" node_number="401"> Please read full Prescribing Information, including Boxed Warnings, and Medication Guide for XARELTO<sup class="valid" valid="valid" title="valid: True, node: 402, level: 11" node_number="402">&#174;</sup>. </p> <p class="valid" valid="valid" title="valid: True, node: 403, level: 10" node_number="403"> Trademarks are those of their respective owners. </p> <p class="valid" valid="valid" title="valid: True, node: 404, level: 10" node_number="404"> cp-53637v6 </p> </div> </div> </div> </div> </div></div><div class="valid" valid="valid" title="valid: True, node: 405, level: 4" node_number="405"> <div class="valid" valid="valid" title="valid: True, node: 406, level: 5" node_number="406"> <p class="valid" valid="valid" title="valid: True, node: 407, level: 6" node_number="407">&#169; Janssen Pharmaceuticals, Inc. 2021May 2021cp-113688v4</p> </div> </div></div></div> <main class="valid" valid="valid" title="valid: True, node: 408, level: 2" node_number="408"> </main> <div class="valid" valid="valid" title="valid: True, node: 409, level: 2" node_number="409"><div class="valid" valid="valid" title="valid: True, node: 410, level: 3" node_number="410"><div class="valid" valid="valid" title="valid: True, node: 411, level: 4" node_number="411">WebMD does not endorse any specific product, service, or treatment.</div></div><div class="valid" valid="valid" title="valid: True, node: 412, level: 3" node_number="412"><div class="valid" valid="valid" title="valid: True, node: 413, level: 4" node_number="413"> <div class="valid" valid="valid" title="valid: True, node: 414, level: 5" node_number="414"> Show More </div> <div class="valid" valid="valid" title="valid: True, node: 415, level: 5" node_number="415"> <div class="valid" valid="valid" title="valid: True, node: 416, level: 6" node_number="416"><div class="valid" valid="valid" title="valid: True, node: 417, level: 7" node_number="417"> <div class="valid" valid="valid" title="valid: True, node: 418, level: 8" node_number="418"> <div class="valid" valid="valid" title="valid: True, node: 419, level: 9" node_number="419"> <div class="valid" valid="valid" title="valid: True, node: 420, level: 10" node_number="420"> <div class="valid" valid="valid" title="valid: True, node: 421, level: 11" node_number="421"> <div class="valid" valid="valid" title="valid: True, node: 422, level: 12" node_number="422"> WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 423, level: 13" node_number="423">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 424, level: 12" node_number="424"> <p class="valid" valid="valid" title="valid: True, node: 425, level: 13" node_number="425">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 426, level: 14" node_number="426">&#174;</sup> is a prescription medicine used to:</p> <ul class="valid" valid="valid" title="valid: True, node: 427, level: 13" node_number="427"> <li class="valid" valid="valid" title="valid: True, node: 428, level: 14" node_number="428"> reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body </li> <li class="valid" valid="valid" title="valid: True, node: 429, level: 14" node_number="429"> treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE) </li> <li class="valid" valid="valid" title="valid: True, node: 430, level: 14" node_number="430"> reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 431, level: 13" node_number="431">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 432, level: 14" node_number="432">&#174;</sup> is used with low dose aspirin to:</p> <ul class="valid" valid="valid" title="valid: True, node: 433, level: 13" node_number="433"> <li class="valid" valid="valid" title="valid: True, node: 434, level: 14" node_number="434"> reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 435, level: 13" node_number="435">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 436, level: 14" node_number="436">&#174;</sup> is safe and effective in children.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 437, level: 11" node_number="437"> <div class="valid" valid="valid" title="valid: True, node: 438, level: 12" node_number="438">WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 439, level: 13" node_number="439">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 440, level: 12" node_number="440"> <p class="valid" valid="valid" title="valid: True, node: 441, level: 13" node_number="441">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 442, level: 14" node_number="442">&#174;</sup> is a prescription medicine used to:</p> <ul class="valid" valid="valid" title="valid: True, node: 443, level: 13" node_number="443"> <li class="valid" valid="valid" title="valid: True, node: 444, level: 14" node_number="444">reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 445, level: 13" node_number="445">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 446, level: 14" node_number="446">&#174;</sup> is safe and effective in children.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 447, level: 11" node_number="447"> <div class="valid" valid="valid" title="valid: True, node: 448, level: 12" node_number="448">WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 449, level: 13" node_number="449">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 450, level: 12" node_number="450"> <p class="valid" valid="valid" title="valid: True, node: 451, level: 13" node_number="451">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 452, level: 14" node_number="452">&#174;</sup> is a prescription medicine used to:</p> <ul class="valid" valid="valid" title="valid: True, node: 453, level: 13" node_number="453"> <li class="valid" valid="valid" title="valid: True, node: 454, level: 14" node_number="454">treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE)</li> <li class="valid" valid="valid" title="valid: True, node: 455, level: 14" node_number="455">reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 456, level: 13" node_number="456">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 457, level: 14" node_number="457">&#174;</sup> is safe and effective in children.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 458, level: 11" node_number="458"> <div class="valid" valid="valid" title="valid: True, node: 459, level: 12" node_number="459">WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 460, level: 13" node_number="460">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 461, level: 12" node_number="461"> <p class="valid" valid="valid" title="valid: True, node: 462, level: 13" node_number="462">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 463, level: 14" node_number="463">&#174;</sup> is a prescription medicine used with low dose aspirin to:</p> <ul class="valid" valid="valid" title="valid: True, node: 464, level: 13" node_number="464"> <li class="valid" valid="valid" title="valid: True, node: 465, level: 14" node_number="465">reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 466, level: 13" node_number="466">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 467, level: 14" node_number="467">&#174;</sup> is safe and effective in children.</p> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 468, level: 10" node_number="468"> <h3 class="valid" valid="valid" title="valid: True, node: 469, level: 11" node_number="469">IMPORTANT SAFETY INFORMATION</h3> <p class="valid" valid="valid" title="valid: True, node: 470, level: 11" node_number="470">WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT XARELTO<sup class="valid" valid="valid" title="valid: True, node: 471, level: 12" node_number="471">&#174;</sup>?</p> <p class="valid" valid="valid" title="valid: True, node: 472, level: 11" node_number="472"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 473, level: 12" node_number="473">&#174;</sup> may cause serious side effects, including: </p> <ul class="valid" valid="valid" title="valid: True, node: 474, level: 11" node_number="474"> <li class="valid" valid="valid" title="valid: True, node: 475, level: 12" node_number="475"> Increased risk of blood clots if you stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 476, level: 13" node_number="476">&#174;</sup>. People with atrial fibrillation (an irregular heart beat) that is not caused by a heart valve problem (nonvalvular) are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a stroke, or to other parts of the body. XARELTO<sup class="valid" valid="valid" title="valid: True, node: 477, level: 13" node_number="477">&#174;</sup> lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 478, level: 13" node_number="478">&#174;</sup>, you may have increased risk of forming a clot in your blood. </li> <li class="valid" valid="valid" title="valid: True, node: 479, level: 12" node_number="479"> Do not stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 480, level: 13" node_number="480">&#174;</sup> without talking to the doctor who prescribes it for you. Stopping XARELTO<sup class="valid" valid="valid" title="valid: True, node: 481, level: 13" node_number="481">&#174;</sup> increases your risk of having a stroke. If you have to stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 482, level: 13" node_number="482">&#174;</sup>, your doctor may prescribe another blood thinner medicine to prevent a blood clot from forming. </li> <li class="valid" valid="valid" title="valid: True, node: 483, level: 12" node_number="483"> Increased risk of bleeding. XARELTO<sup class="valid" valid="valid" title="valid: True, node: 484, level: 13" node_number="484">&#174;</sup> can cause bleeding which can be serious, and may lead to death. This is because XARELTO<sup class="valid" valid="valid" title="valid: True, node: 485, level: 13" node_number="485">&#174;</sup> is a blood thinner medicine (anticoagulant) that lowers blood clotting. During treatment with XARELTO<sup class="valid" valid="valid" title="valid: True, node: 486, level: 13" node_number="486">&#174;</sup> you are likely to bruise more easily, and it may take longer for bleeding to stop. You may be at higher risk of bleeding if you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 487, level: 13" node_number="487">&#174;</sup> and have certain other medical problems. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 488, level: 11" node_number="488"> You may have a higher risk of bleeding if you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 489, level: 12" node_number="489">&#174;</sup> and take other medicines that increase your risk of bleeding, including: </p> <ul class="valid" valid="valid" title="valid: True, node: 490, level: 11" node_number="490"> <li class="valid" valid="valid" title="valid: True, node: 491, level: 12" node_number="491">Aspirin or aspirin-containing products</li> <li class="valid" valid="valid" title="valid: True, node: 492, level: 12" node_number="492">Long-term (chronic) use of non-steroidal anti-inflammatory drugs (NSAIDs)</li> <li class="valid" valid="valid" title="valid: True, node: 493, level: 12" node_number="493">Warfarin sodium (Coumadin<sup class="valid" valid="valid" title="valid: True, node: 494, level: 13" node_number="494">&#174;</sup>, Jantoven<sup class="valid" valid="valid" title="valid: True, node: 495, level: 13" node_number="495">&#174;</sup>)</li> <li class="valid" valid="valid" title="valid: True, node: 496, level: 12" node_number="496">Any medicine that contains heparin</li> <li class="valid" valid="valid" title="valid: True, node: 497, level: 12" node_number="497">Clopidogrel (Plavix<sup class="valid" valid="valid" title="valid: True, node: 498, level: 13" node_number="498">&#174;</sup>)</li> <li class="valid" valid="valid" title="valid: True, node: 499, level: 12" node_number="499">Selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)</li> <li class="valid" valid="valid" title="valid: True, node: 500, level: 12" node_number="500">Other medicines to prevent or treat blood clots</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 501, level: 11" node_number="501"> Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above. </p> <p class="valid" valid="valid" title="valid: True, node: 502, level: 11" node_number="502"> Call your doctor or get medical help right away if you develop any of these signs or symptoms of bleeding: </p> <ul class="valid" valid="valid" title="valid: True, node: 503, level: 11" node_number="503"> <li class="valid" valid="valid" title="valid: True, node: 504, level: 12" node_number="504">Unexpected bleeding or bleeding that lasts a long time, such as:</li> </ul> <ul class="valid" valid="valid" title="valid: True, node: 505, level: 11" node_number="505"> <li class="valid" valid="valid" title="valid: True, node: 506, level: 12" node_number="506">Nosebleeds that happen often</li> <li class="valid" valid="valid" title="valid: True, node: 507, level: 12" node_number="507">Unusual bleeding from gums</li> <li class="valid" valid="valid" title="valid: True, node: 508, level: 12" node_number="508">Menstrual bleeding that is heavier than normal, or vaginal bleeding</li> </ul> <ul class="valid" valid="valid" title="valid: True, node: 509, level: 11" node_number="509"> <li class="valid" valid="valid" title="valid: True, node: 510, level: 12" node_number="510">Bleeding that is severe or you cannot control</li> <li class="valid" valid="valid" title="valid: True, node: 511, level: 12" node_number="511">Red, pink, or brown urine</li> <li class="valid" valid="valid" title="valid: True, node: 512, level: 12" node_number="512">Bright red or black stools (looks like tar)</li> <li class="valid" valid="valid" title="valid: True, node: 513, level: 12" node_number="513">Cough up blood or blood clots</li> <li class="valid" valid="valid" title="valid: True, node: 514, level: 12" node_number="514">Vomit blood or your vomit looks like "coffee grounds"</li> <li class="valid" valid="valid" title="valid: True, node: 515, level: 12" node_number="515">Headaches, feeling dizzy or weak</li> <li class="valid" valid="valid" title="valid: True, node: 516, level: 12" node_number="516">Pain, swelling, or new drainage at wound sites</li> </ul> <li class="valid" valid="valid" title="valid: True, node: 517, level: 11" node_number="517"> Spinal or epidural blood clots (hematoma).&#160;People who take a blood thinner medicine (anticoagulant) like XARELTO<sup class="valid" valid="valid" title="valid: True, node: 518, level: 12" node_number="518">&#174;</sup>, and have medicine injected into their spinal and epidural area, or have a spinal puncture, have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis). Your risk of developing a spinal or epidural blood clot is higher if: <ul class="valid" valid="valid" title="valid: True, node: 519, level: 12" node_number="519"> <li class="valid" valid="valid" title="valid: True, node: 520, level: 13" node_number="520"> A thin tube called an epidural catheter is placed in your back to give you certain medicine </li> <li class="valid" valid="valid" title="valid: True, node: 521, level: 13" node_number="521"> You take NSAIDs or a medicine to prevent blood from clotting </li> <li class="valid" valid="valid" title="valid: True, node: 522, level: 13" node_number="522"> You have a history of difficult or repeated epidural or spinal punctures </li> <li class="valid" valid="valid" title="valid: True, node: 523, level: 13" node_number="523"> You have a history of problems with your spine or have had surgery on your spine </li> </ul> </li> <p class="valid" valid="valid" title="valid: True, node: 524, level: 11" node_number="524"> If you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 525, level: 12" node_number="525">&#174;</sup> and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots. Tell your doctor right away if you have back pain, tingling, numbness, muscle weakness (especially in your legs and feet), or loss of control of the bowels or bladder (incontinence). </p> <p class="valid" valid="valid" title="valid: True, node: 526, level: 11" node_number="526"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 527, level: 12" node_number="527">&#174;</sup> is not for use in people with artificial heart valves. </p> <p class="valid" valid="valid" title="valid: True, node: 528, level: 11" node_number="528"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 529, level: 12" node_number="529">&#174;</sup> is not for use in people with antiphospholipid syndrome (APS), especially with positive triple antibody testing. </p> <p class="valid" valid="valid" title="valid: True, node: 530, level: 11" node_number="530"> &#8203;&#8203;Do not take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 531, level: 12" node_number="531">&#174;</sup> if you: </p> <ul class="valid" valid="valid" title="valid: True, node: 532, level: 11" node_number="532"> <li class="valid" valid="valid" title="valid: True, node: 533, level: 12" node_number="533"> Currently have certain types of abnormal bleeding. Talk to your doctor before taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 534, level: 13" node_number="534">&#174;</sup> if you currently have unusual bleeding. </li> <li class="valid" valid="valid" title="valid: True, node: 535, level: 12" node_number="535"> Are allergic to rivaroxaban or any of the ingredients of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 536, level: 13" node_number="536">&#174;</sup>. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 537, level: 11" node_number="537"> &#8203;&#8203;Before taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 538, level: 12" node_number="538">&#174;</sup>, tell your doctor about all your medical conditions, including if you: </p> <ul class="valid" valid="valid" title="valid: True, node: 539, level: 11" node_number="539"> <li class="valid" valid="valid" title="valid: True, node: 540, level: 12" node_number="540"> Have ever had bleeding problems </li> <li class="valid" valid="valid" title="valid: True, node: 541, level: 12" node_number="541"> Have liver or kidney problems </li> <li class="valid" valid="valid" title="valid: True, node: 542, level: 12" node_number="542"> Have antiphospholipid syndrome (APS) </li> <li class="valid" valid="valid" title="valid: True, node: 543, level: 12" node_number="543"> Are pregnant or plan to become pregnant. It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 544, level: 13" node_number="544">&#174;</sup> will harm your unborn baby. <ul class="valid" valid="valid" title="valid: True, node: 545, level: 13" node_number="545"> <li class="valid" valid="valid" title="valid: True, node: 546, level: 14" node_number="546"> Tell your doctor right away if you become pregnant during treatment with XARELTO<sup title="valid: False, node: 547, level: 15" node_number="547">&#174;</sup>. Taking XARELTO<sup title="valid: False, node: 548, level: 15" node_number="548">&#174;</sup> while you are pregnant may increase the risk of bleeding in you or in your unborn baby. </li> <li class="valid" valid="valid" title="valid: True, node: 549, level: 14" node_number="549"> If you take XARELTO<sup title="valid: False, node: 550, level: 15" node_number="550">&#174;</sup> during pregnancy, tell your doctor right away if you have any signs or symptoms of bleeding or blood loss.&#160;See &#8220;What is the most important information I should know about XARELTO<sup title="valid: False, node: 551, level: 15" node_number="551">&#174;</sup>?&#8221; for signs and symptoms of bleeding. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 552, level: 12" node_number="552"> Are breastfeeding or plan to breastfeed. XARELTO<sup class="valid" valid="valid" title="valid: True, node: 553, level: 13" node_number="553">&#174;</sup> may pass into your breast milk. Talk to your doctor about the best way to feed your baby during treatment with XARELTO<sup class="valid" valid="valid" title="valid: True, node: 554, level: 13" node_number="554">&#174;</sup>. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 555, level: 11" node_number="555"> Tell all of your doctors and dentists that you are taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 556, level: 12" node_number="556">&#174;</sup>. They should talk to the doctor who prescribed XARELTO<sup class="valid" valid="valid" title="valid: True, node: 557, level: 12" node_number="557">&#174;</sup> for you before you have any surgery, medical or dental procedure. </p> <p class="valid" valid="valid" title="valid: True, node: 558, level: 11" node_number="558"> Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements<b class="valid" valid="valid" title="valid: True, node: 559, level: 12" node_number="559">. </b> </p> <p class="valid" valid="valid" title="valid: True, node: 560, level: 11" node_number="560"> Some of your other medicines may affect the way XARELTO<sup class="valid" valid="valid" title="valid: True, node: 561, level: 12" node_number="561">&#174;</sup> works, causing side effects. Certain medicines may increase your risk of bleeding. See &#8220;What is the most important information I should know about XARELTO<sup class="valid" valid="valid" title="valid: True, node: 562, level: 12" node_number="562">&#174;</sup>?&#8221; </p> <p class="valid" valid="valid" title="valid: True, node: 563, level: 11" node_number="563"> HOW SHOULD I TAKE XARELTO<sup class="valid" valid="valid" title="valid: True, node: 564, level: 12" node_number="564">&#174;</sup>? </p> <ul class="valid" valid="valid" title="valid: True, node: 565, level: 11" node_number="565"> <li class="valid" valid="valid" title="valid: True, node: 566, level: 12" node_number="566"> Take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 567, level: 13" node_number="567">&#174;</sup> exactly as prescribed by your doctor. </li> <li class="valid" valid="valid" title="valid: True, node: 568, level: 12" node_number="568"> Do not change your dose or stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 569, level: 13" node_number="569">&#174;</sup> unless your doctor tells you to. Your doctor may change your dose if needed. </li> <li class="valid" valid="valid" title="valid: True, node: 570, level: 12" node_number="570"> Your doctor will decide how long you should take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 571, level: 13" node_number="571">&#174;</sup>. </li> <li class="valid" valid="valid" title="valid: True, node: 572, level: 12" node_number="572"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 573, level: 13" node_number="573">&#174;</sup> may need to be stopped for one or more days before any surgery or medical or dental procedure. Your doctor will tell you when to stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 574, level: 13" node_number="574">&#174;</sup> and when to start taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 575, level: 13" node_number="575">&#174;</sup> again after your surgery or procedure. </li> <li class="valid" valid="valid" title="valid: True, node: 576, level: 12" node_number="576"> If you need to stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 577, level: 13" node_number="577">&#174;</sup> for any reason, talk to the doctor who prescribed XARELTO<sup class="valid" valid="valid" title="valid: True, node: 578, level: 13" node_number="578">&#174;</sup> to you to find out when you should stop taking it. Do not stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 579, level: 13" node_number="579">&#174;</sup> without first talking to the doctor who prescribes it to you. </li> <li class="valid" valid="valid" title="valid: True, node: 580, level: 12" node_number="580"> If you have difficulty swallowing XARELTO<sup class="valid" valid="valid" title="valid: True, node: 581, level: 13" node_number="581">&#174;</sup> tablets whole, talk to your doctor about other ways to take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 582, level: 13" node_number="582">&#174;</sup>. </li> <li class="valid" valid="valid" title="valid: True, node: 583, level: 12" node_number="583"> Do not run out of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 584, level: 13" node_number="584">&#174;</sup>. Refill your prescription of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 585, level: 13" node_number="585">&#174;</sup> before you run out. When leaving the hospital following a hip or knee replacement, be sure that you will have XARELTO<sup class="valid" valid="valid" title="valid: True, node: 586, level: 13" node_number="586">&#174;</sup> available to avoid missing any doses. </li> <li class="valid" valid="valid" title="valid: True, node: 587, level: 12" node_number="587"> If you take too much XARELTO<sup class="valid" valid="valid" title="valid: True, node: 588, level: 13" node_number="588">&#174;</sup>, go to the nearest hospital emergency room or call your doctor right away. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 589, level: 11" node_number="589"> If you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 590, level: 12" node_number="590">&#174;</sup> for:&#8203; </p> <ul class="valid" valid="valid" title="valid: True, node: 591, level: 11" node_number="591"> <ul class="valid" valid="valid" title="valid: True, node: 592, level: 12" node_number="592"> <li class="valid" valid="valid" title="valid: True, node: 593, level: 13" node_number="593"> Atrial Fibrillation that is not caused by a heart valve problem: <ul class="valid" valid="valid" title="valid: True, node: 594, level: 14" node_number="594"> <li title="valid: False, node: 595, level: 15" node_number="595"> Take XARELTO<sup title="valid: False, node: 596, level: 16" node_number="596">&#174;</sup> 1 time a day with your evening meal. </li> <li title="valid: False, node: 597, level: 15" node_number="597"> If you miss a dose of XARELTO<sup title="valid: False, node: 598, level: 16" node_number="598">&#174;</sup>, take it as soon as you remember on the same day.&#160;Take your next dose at your regularly scheduled time. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 599, level: 13" node_number="599"> Blood clots in the veins of your legs or lungs: <ul class="valid" valid="valid" title="valid: True, node: 600, level: 14" node_number="600"> <li title="valid: False, node: 601, level: 15" node_number="601"> Take XARELTO<sup title="valid: False, node: 602, level: 16" node_number="602">&#174;&#160;</sup>1 or 2 times a day as prescribed by your doctor. </li> <li title="valid: False, node: 603, level: 15" node_number="603"> For the 10-mg dose, XARELTO<sup title="valid: False, node: 604, level: 16" node_number="604">&#174;</sup> may be taken with or without food. </li> <li title="valid: False, node: 605, level: 15" node_number="605"> For the 15-mg and 20-mg doses, take XARELTO<sup title="valid: False, node: 606, level: 16" node_number="606">&#174;</sup> with food at the same time each day. </li> <li title="valid: False, node: 607, level: 15" node_number="607"> If you miss a dose: <ul title="valid: False, node: 608, level: 16" node_number="608"> <li title="valid: False, node: 609, level: 17" node_number="609"> If you take the 15-mg dose of XARELTO<sup title="valid: False, node: 610, level: 18" node_number="610">&#174;</sup> 2 times a day (a total of 30 mg of XARELTO<sup title="valid: False, node: 611, level: 18" node_number="611">&#174;</sup> in 1 day):&#160;Take XARELTO<sup title="valid: False, node: 612, level: 18" node_number="612">&#174;</sup> as soon as you remember on the same day. You may take 2 doses at the same time to make up for the missed dose. Take your next dose at your regularly scheduled time. </li> <li title="valid: False, node: 613, level: 17" node_number="613"> If you take XARELTO<sup title="valid: False, node: 614, level: 18" node_number="614">&#174;</sup> 1 time a day: Take XARELTO<sup title="valid: False, node: 615, level: 18" node_number="615">&#174;</sup> as soon as you remember on the same day. Take your next dose at your regularly scheduled time.&#8203; </li> </ul> </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 616, level: 13" node_number="616"> Hip or knee replacement surgery: <ul class="valid" valid="valid" title="valid: True, node: 617, level: 14" node_number="617"> <li title="valid: False, node: 618, level: 15" node_number="618"> Take XARELTO<sup title="valid: False, node: 619, level: 16" node_number="619">&#174;</sup> 1 time a day with or without food. </li> <li title="valid: False, node: 620, level: 15" node_number="620"> If you miss a dose of XARELTO<sup title="valid: False, node: 621, level: 16" node_number="621">&#174;</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 622, level: 13" node_number="622"> Blood clots in people hospitalized for an acute illness: <ul class="valid" valid="valid" title="valid: True, node: 623, level: 14" node_number="623"> <li title="valid: False, node: 624, level: 15" node_number="624"> Take XARELTO<sup title="valid: False, node: 625, level: 16" node_number="625">&#174;</sup>&#160;1&#160;time a day, with or without food, while you are in the hospital and after you are discharged as prescribed by your doctor. </li> <li title="valid: False, node: 626, level: 15" node_number="626"> If you miss a dose of XARELTO<sup title="valid: False, node: 627, level: 16" node_number="627">&#174;</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 628, level: 13" node_number="628"> Reducing the risk of serious heart problems, heart attack and stroke in coronary artery&#160;disease or peripheral artery disease: <ul class="valid" valid="valid" title="valid: True, node: 629, level: 14" node_number="629"> <li title="valid: False, node: 630, level: 15" node_number="630"> Take XARELTO<sup title="valid: False, node: 631, level: 16" node_number="631">&#174;</sup>&#160;2.5 mg 2&#160;times a day with or without food. </li> <li title="valid: False, node: 632, level: 15" node_number="632"> If you miss a dose of XARELTO<sup title="valid: False, node: 633, level: 16" node_number="633">&#174;</sup>, take your next dose at your regularly scheduled time. </li> <li title="valid: False, node: 634, level: 15" node_number="634"> Take aspirin 75 to 100 mg once daily as instructed by your doctor. </li> </ul> </li> </ul> </ul> <div class="valid" valid="valid" title="valid: True, node: 635, level: 11" node_number="635"> <p class="valid" valid="valid" title="valid: True, node: 636, level: 12" node_number="636"> WHAT ARE THE POSSIBLE SIDE EFFECTS OF <span class="valid" valid="valid" title="valid: True, node: 637, level: 13" node_number="637">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 638, level: 14" node_number="638">&#174;</sup>?</span> </p> <p class="valid" valid="valid" title="valid: True, node: 639, level: 12" node_number="639"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 640, level: 13" node_number="640">&#174;</sup> may cause serious side effects: </p> <ul class="valid" valid="valid" title="valid: True, node: 641, level: 12" node_number="641"> <li class="valid" valid="valid" title="valid: True, node: 642, level: 13" node_number="642"> See &#8220;What is the most important information I should know about XARELTO<sup class="valid" valid="valid" title="valid: True, node: 643, level: 14" node_number="643">&#174;</sup>?&#8221; </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 644, level: 12" node_number="644"> The most common side effect of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 645, level: 13" node_number="645">&#174;</sup> was bleeding. </p> <p class="valid" valid="valid" title="valid: True, node: 646, level: 12" node_number="646"> Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Janssen Pharmaceuticals, Inc., at 1-800-JANSSEN (1-800-526-7736). </p> <p class="valid" valid="valid" title="valid: True, node: 647, level: 12" node_number="647"> Please read full <a class="valid" valid="valid" title="valid: True, node: 648, level: 13" node_number="648">Prescribing Information</a>, including Boxed Warnings, and <a class="valid" valid="valid" title="valid: True, node: 649, level: 13" node_number="649">Medication Guide</a> for XARELTO<sup class="valid" valid="valid" title="valid: True, node: 650, level: 13" node_number="650">&#174;</sup>. </p> <p class="valid" valid="valid" title="valid: True, node: 651, level: 12" node_number="651"> Trademarks are those of their respective owners. </p> <p class="valid" valid="valid" title="valid: True, node: 652, level: 12" node_number="652"> cp-53637v6 </p> </div> </div> </div> </div> </div></div> </div> </div> </div></div> </body>
        <style tyle='text/css'>
body{
    position: relative;
    padding-left: 30px;
    top: 60px;
}
* {
    border: 1px solid #eee;
    padding: 5px 12px;
    margin: 3px 0;
    box-sizing: content-box;
    background-color: #fff;
    cursor: no-drop;
}
main:hover > *, section:hover > *, header:hover > *, nav:hover > *, a:hover > *, div:hover > *, p:hover > *, ul:hover > *, h1:hover > *, h2:hover > *, h3:hover > *, li:hover > *, span:hover > *{
    border: 2px solid green;
    background-color: #fffeee;
    padding: 5px 23px !important;
    margin: 1px 0;
    color: green;
}
main:hover, section:hover, header:hover, nav:hover, a:hover, div:hover, p:hover, ul:hover, h1:hover, h2:hover, h3:hover, li:hover, span:hover{
    border: 1px solid #fff;
    background-color: #eee;
}
a, span {
    display: block;
}
.selected {
    border: 2px solid orchid !important;
    opacity: 0.8;
    color: orchid !important;
}
.selected * {
    padding: 2px !important;
    color: orchid !important;
}
.valid {
  cursor: pointer;
}
.btn{
  cursor: pointer;
  font-weight: bolder;
  padding: 8px;
}
</style> 
        <script>function OpenOriginalLink($event){
    $event.stopPropagation();
    console.log(url);
}

function removeItem($event){
    $event.stopPropagation();
    console.log('Remove item: ', url)
    localStorage.removeItem(url)
}

function exportData($event){
    $event.stopPropagation();

    result = []
    for(let i=0; i<localStorage.length; i++) {
        let key = localStorage.key(i);
        result.push(localStorage.getItem(key))
    }
    const _url = URL.createObjectURL(new Blob([result.join("\n")], {type: 'text/plain'}))
    $event.target.href = _url;
    localStorage.clear()
}

var removeItemBtn = document.createElement("BUTTON");   // Create a <button> element
removeItemBtn.innerHTML = "Remove Item";
removeItemBtn.classList.add('btn');
removeItemBtn.style.position = "fixed";
removeItemBtn.style.left = '5px';
removeItemBtn.style.top = 0;
removeItemBtn.style.border = "1px solid";
removeItemBtn.style.boxShadow = "3px 3px #888";
removeItemBtn.onclick = removeItem;
document.body.appendChild(removeItemBtn);

var goToOriginLink = document.createElement("A");   // Create a <button> element
goToOriginLink.innerHTML = "GoToOrigin";
goToOriginLink.classList.add('btn');
goToOriginLink.style.position = "fixed"
goToOriginLink.style.left = '115px'
goToOriginLink.style.top = 0;
goToOriginLink.onclick = OpenOriginalLink;
goToOriginLink.setAttribute('href', decodeURIComponent(url));
goToOriginLink.target = '_blank';
document.body.appendChild(goToOriginLink);

var current = new Date
var exportDataLink = document.createElement("A");   // Create a <button> element
exportDataLink.innerHTML = "Export data";
exportDataLink.classList.add('btn');
exportDataLink.download = current.toISOString() + '.exported.txt';
exportDataLink.style.position = "fixed";
exportDataLink.style.right = '5px';
exportDataLink.style.top = 0;
exportDataLink.style.border = "1px solid #888";
exportDataLink.style.boxShadow = "3px 3px #888";
exportDataLink.onclick = exportData;
document.body.appendChild(exportDataLink);

data = {
    'title': null ,
    'article': null
}

var body = document.getElementsByTagName("body")[0];

body.onclick = function($e){
    var num = $e.target.getAttribute('node_number')
    var valid = $e.target.getAttribute('valid')

    if(!valid){
        console.log("Element is invalid")
        return
    }

    if(data.length > 2){
        data = data.splice(0, 2)
    }

    console.log("node:", $e.target)

    if(!data.title && !data.article){
        data.title = num;
        console.log("data:", data)
        $e.target.classList.add('selected')
    }else if (data.title && !data.article){
        data.article = num;
        console.log("data:", data)
        $e.target.classList.add('selected')
    }else{
        selected = Array.from(document.getElementsByClassName("selected"))
        selected.forEach(function(el){
            el.classList.remove('selected')
        })

        data.title = num;
        data.article = null;
        $e.target.classList.add('selected')

    }

    if(data.title && data.article){
        var obj = {
            url: url,
            text: body_html,
            title: data.title,
            article: data.article,
        }

        var datasetItem = JSON.stringify(obj)
        localStorage.setItem(url, datasetItem)
    }
}
</script> 
      </html>